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ABSTRACT OF DISSERTATION 
 
 
 
 
 
LOSS OF MRP1 POTENTIATES DOXORUBICIN-INDUCED  
CARDIOTOXICITY IN MICE 
 
Doxorubicin (DOX) is a broad-spectrum and effective chemotherapeutic agent, 
but its use in oncologic practice is limited by dose-dependent cumulative 
cardiotoxicity.  DOX-induced cardiotoxicity is in large part due to its ability to 
cause oxidative stress.  Multidrug resistance associated protein 1 (MRP1/ABCC1) 
is a member of the ATP-binding cassette (ABC) transporter superfamily. By 
effluxing a wide variety of endogenous and exogenous substrates, Mrp1 plays 
important physiological roles in multiple tissues and also protects normal tissues 
against toxicants.  However, the role of MRP1 in heart is largely unknown.   
 
The role of Mrp1 in DOX-induced cardiotoxicity was investigated in Mrp1 null 
(Mrp1-/-) and their C57BL (WT) littermates.  Chronic DOX caused body weight 
loss and hemotoxicity, and these adverse effects were significantly exacerbated 
in Mrp1-/- vs WT mice.  Importantly, loss of Mrp1 potentiated DOX-induced 
cardiotoxicity, presenting as worsened cardiac function and more cellular 
apoptosis in DOX treated Mrp1-/- mice.  Mrp1 also protected neonatal mouse 
cardiomyocytes (CM) and cardiac fibroblasts (CF) culture against DOX 
cytotoxicity in vitro. This was demonstrated by the decreased cell survival, more 
apoptosis and more DNA damage in DOX treated Mrp1-/- vs WT cells.     
 
In addition, the effects of deletion of Mrp1 was studied on glutathione 
(GSH)/glutathione disulfide (GSSG) homeostasis, glutathione conjugate of 4-
hydroxy-2-nonenal (GS-HNE) accumulation, protein oxidative damage and 
expression of antioxidant enzymes.  Loss of Mrp1 led to significantly higher GSH 
and GSSG basal levels in heart.  Following DOX treatment, Mrp1-/- CM and CF 
showed increased GSH and GSSG levels vs WT cells.  Meanwhile, DOX 
increased expression of the GSH synthesis enzymes in Mrp1-/- but not WT cells.  
Thus, increased GSH synthesis may contribute to the further increase in the 
GSH pool in DOX-treated Mrp1-/- cells. DOX induced comparable increases of 
GS-HNE concentration in WT and Mrp1-/- mice hearts.  Finally, expression of 
 extracellular superoxide dismutase (ECSOD/SOD3) was significantly lower in 
Mrp1-/- vs.  WT CM treated with either saline or DOX.    
 
    In summary, this study is the first to document a protective role of Mrp1 in 
DOX-induced cardiotoxicity.  It gives critical information regarding the potential 
adverse sequelae of introduction of MRP1 inhibitors as adjuncts to clinical 
chemotherapy of multidrug resistant tumors. 
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Chapter One 
 
Introduction 
 
Overview 
    Chemotherapy usually refers to the use of chemical substances to treat cancer.  
It is one of the three main methods utilized to treat cancer, and may be used in 
conjunction with two other methods, radiation therapy and surgery.  However, 
side effects induced by chemotherapy occurring in off-target organs sometimes 
significantly limit its clinic use.  Acute toxicity induced by chemotherapy is usually 
due to the toxic effects on rapidly dividing normal cells, like hematological toxicity 
and gastrointestinal toxicity.  In contrast, the late toxicity of chemotherapy is more 
complex and more difficult to be treated.  Actually, in the last few decades, 
because of the advances in cancer treatment, more patients are becoming long-
term survivors of this disease.  Therefore, it is becoming increasingly important to 
understand how chemotherapy causes long-term adverse effects and how we 
might prevent them.  The long-term effects of chemotherapy mainly include 
cardiac toxicity, pulmonary toxicity, impairment of fertility and secondary cancers.  
Among them, cardiac toxicity is one of the most severe side effects.  It can occur 
within days, months or even years after treatment and it leads to an important 
increase of morbidity and mortality in patients receiving chemotherapy.  
    Doxorubicin (DOX) is a commonly used anthracycline chemotherapy agent for 
a wide variety of cancers.  Large scale clinical studies show that DOX 
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significantly increases the incidence of heart failure in cancer patients.  Studies in 
animal models and in vitro cell culture also demonstrate that DOX promotes the 
generation of reactive oxygen species (ROS) and causes oxidative stress in 
heart tissue or cardiomyocytes.  Understanding the defense mechanisms of 
normal heart tissue against DOX toxicity will be very helpful to identify 
susceptible patients in the clinic and also identify potential ways to relieve or 
even prevent DOX-induced adverse effects in heart. 
Multidrug resistance-associated protein 1 (MRP1/ABCC1) is a member of 
ATP-binding cassette (ABC) transporter superfamily.  It is ubiquitously expressed 
in multiple tissues and utilizes the energy of ATP hydrolysis to actively transport 
a wide variety of compounds across biological membranes (cell or organelle 
membranes).   It has been demonstrated to mediate a protective role in multiple 
organs through the excretion of toxic compounds and their metabolites.  Recently, 
there is growing evidence showing that single nucleotide polymorphisms (SNPs) 
of MRP1 are associated with cancer patients’ susceptibility to DOX-induced 
cardiotoxicity.  But the underlying mechanism is not clear.  Previous work in our 
laboratory found that one of these SNPs (Gly671Val) impairs by more than 85% 
MRP1’s activity in effluxing glutathione conjugated 4-Hydroxy-2-nonenal (GS-
HNE), and HEK cells that overexpress MRP1 (Gly671Val) are more sensitive to 
DOX toxicity compared to WT MRP1.  Additional previous work in our laboratory 
found that after a single intravenous administration of DOX, Mrp1 null (Mrp1-/-) 
mice have more nuclear injury in heart compared to their wild type (WT) 
littermates.  Thus, I hypothesize that MRP1 protects the heart against DOX 
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toxicity by effluxing the toxic products.  This study explored the potential 
protective function of Mrp1 in DOX-induced cardiotoxicity in vivo and in vitro. 
 
Doxorubicin (DOX)  
DOX and its medical use in cancer treatment 
    DOX, also known by its trade name Adriamycin, is an anthracycline antibiotic 
chemotherapeutic drug derived from the bacterium Streptomyces peucetius var. 
caesius (Arcamone et al., 1969).  It is one of the most potent anti-cancer agents 
and it is prescribed in isolation or in association with other drugs.  DOX is used to 
treat a wide variety of cancers in multiple organs, including gynecological (breast, 
endometrium, ovary), urogenital (bladder, testicle), endocrine (thyroid, pancreas), 
gastrointestinal (stomach), and lung cancer.  It is also effective in sarcomas 
(neuroblastoma, Ewing sarcoma, and osteosarcoma), acute lymphocytic and 
myeloid leukemia, and lymphomas (Minotti et al., 2004; Octavia et al., 2012).  In 
the clinic, DOX is administered strictly by intravenous infusion.  If the medication 
escapes from the vein, it can cause tissue irritation or damage.  The dose and 
how often the medicine is given depends on patients’ body size, blood counts, 
hepatic function, and the type of cancer being treated. 
 
DOX induces cardiotoxicity 
    Despite its excellent clinical efficacy as a chemotherapeutic agent, the clinical 
usage of DOX has been restricted due to its potential to induce serious side 
effects in cancer patients, including low white blood cell counts with increased 
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risk of infection, low platelet counts with increased risk of bleeding, hair loss or 
thinning, nausea, vomiting and the most severe one - cardiotoxicity (Minotti et al., 
2004; Dolye et al., 2005).  Clinical studies clearly show that the incidence of heart 
failure rises rapidly once the cumulative dose of DOX exceeds 550 mg/m2 in 
cancer patients (Von Hoff et al., 1979; Swain et al., 2003).  For example, the 
incidence of heart failure is nearly 2% with a cumulative DOX dose of 300 
mg/m2 but rapidly increases to 20% at cumulative doses in excess of 550 mg/m2 
(Christiansen et al., 2006).  In addition, the risk of heart failure is higher in 
individuals with a history of cardiomyopathy, mediastinal irradiation and heart 
disease (Chatterjee et al., 2010).  Since the incidence of heart failure is highly 
dependent on how long these patients are being followed, it is now well-accepted 
that there is no absolutely safe dose of DOX for the heart.  This means that the 
risk of developing heart failure in cancer patients treated with DOX remains a life-
long threat.  
    Clinically, DOX-induced cardiotoxicity can occur acutely (during administration 
or on the day when treatment is given), subacutely (several days to months 
following administration), or be delayed (years to decades following exposure).  
Acute cardiotoxicity is uncommon.  The incidence particularly increases when the 
cumulative dose exceeds 550 mg/m2.  It can consist of arrhythmias, a peri-
myocarditis syndrome or electrocardiographic abnormalities.  The subacute 
damage develops more insidiously over months, with increasing fatigue, 
tachycardia and eventually pulmonary edema and right heart congestive 
symptoms.  The chronic/delayed cardiotoxicity is the most clinically relevant.  It 
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can result in ventricular dysfunction, heart failure, and arrhythmias years or even 
decades after exposure.  This suggests the need for a continuous follow-up of 
the cardiac status of patients who receive DOX.  Chronic heart damage induced 
by DOX is usually considered to be irreversible.  Thus, DOX-induced 
chronic/delayed cardiac toxicity strongly impacts cancer patients’ quality of life 
and even survival and thus also significantly limits the therapeutic options.   
 
Mechanisms of DOX-induced cardiotoxicity  
    The cancer therapeutic effect of DOX is mainly mediated by its intercalation 
into DNA or to act as a “topoisomerase poison” in dividing cells, causing DNA 
fragmentation, polymerase inhibition, and decreased DNA, RNA and protein 
synthesis (Rabbani et al., 2005).  This mechanism is unlikely to be the major 
contributor in myocardial injury, since the replication of myocytes in heart is less 
active.  A number of mechanisms have been proposed to explain the 
development of DOX-induced cardiotoxicity, including disruption of intracellular 
iron homeostasis (Ducroq et al., 2010), free radical and reactive oxygen species 
(ROS) formation (Minotti et al., 2004; Yen et al., 1996), reduction in the activity of 
endogenous antioxidant enzymes (Li et al., 2000), mitochondrial damage (Green 
et al., 2002), direct interaction with cell death triggers or down-regulation of cell 
survival genes (Poizat et al., 2005; Liu et al., 2008; Park et al., 2011), and 
activation of innate immunity (Nozaki et al., 2004; Riad et al., 2008).  Although 
the mechanism of DOX-induced cardiotoxicity is likely complex and multifactorial, 
one of the most well-accepted hypothesis is that DOX-induced oxidative stress in 
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cardiac tissue through the generation of ROS is a major contributor.  
    This hypothesis states that the superoxide anion (•O2
-) and other reactive ROS 
generated by DOX, which cycles between the quinone and semiquinone, 
contribute significantly to cardiac pathology (Gewirtz, 1999; Minotti et al., 2004).  
First, a DOX molecule accepts one electron from NADH or NADPH to form the 
reduced semiquinone radical of DOX.  In heart, enzymes that can catalyze this 
reaction include mitochondrial NADH dehydrogenases present in the 
sarcoplasmic reticulum and mitochondria as well as cytosolic enzymes such as 
NADPH dehydrogenase, xanthine oxidase and nitric oxide synthases 
(Pawłowska et al., 2003; Nohl et al., 1998; Vásquez-Vivar et al., 1997; Fogli et al., 
2004).  Then, the unpaired electron is donated to molecular oxygen by DOX-
semiquinone, forming •O2
- (Figure 1.1).  Once the •O2
- is produced, the 
dismutation of •O2
- to hydrogen peroxide (H2O2) is catalyzed by superoxide 
dismutase (SOD) or may occur spontaneously.  H2O2 is a relatively stable and 
low-toxicity molecule, and can be eliminated by catalase, glutathione peroxidase 
(Gpx) and thioredoxin peroxidase (Tpx) under physiological conditions.  However, 
in the presence of transition metal ions, especially iron ions, the overproduction 
of H2O2 and •O2
- can be converted through Fenton and Haber-Weiss reaction to 
a large amount of hydroxyl radical (•OH), which has a very short half-life and is 
extremely reactive and toxic.  It reacts with almost any oxidizable compound in its 
vicinity and thus induces damage to all types of macromolecules, including lipids, 
nucleic acids, and proteins.  Among these macromolecular damages, lipid 
peroxidation is probably the most important.  The lipid peroxidation can result in 
7 
 
severe membrane dysfunction and significant damage to mitochondrial structural 
integrity and function.  Therefore, it is the ROS released by this DOX redox 
cycling, rather than DOX itself that is most likely responsible for drug induced 
adverse cardiotoxicity. 
    A body of evidence in animal models supports the hypothesis that ROS 
contributes to DOX-induced cardiotoxicity.  For example:  chronic DOX 
cardiotoxicity has been associated with a marked drop in expression of the 
antioxidant enzyme manganese superoxide dismutase (MnSOD) (Li et al., 2000; 
Stěrba et al., 2011), while overexpression of MnSOD protects mitochondrial 
complex I against DOX-induced cardiotoxicity in MnSOD transgenic mice (Yen et 
al., 1996; Yen et al., 1999).  The overexpression of glutathione peroxidase (Gpx) 
protects the isolated mouse heart from toxicity induced by DOX perfusion, as well 
as heart damage in mice treated with single high dose of DOX (15 mg/kg) (Xiong 
et al., 2006).  Furthermore, multiple antioxidant molecules show promising 
protective effects in myocyte cell culture study or small animal studies (Oliveira et 
al., 2004; Lou et al., 2005; Singal et al., 2000).  
    This importance of antioxidant enzymes and molecules in protecting against 
DOX-induced cardiotoxicity also provides some explanation of why the heart is 
particularly susceptible to DOX.  First, the heart has a large density/volume of 
mitochondria because it requires large amounts of energy.  However, 
mitochondria are both important sources of ROS formation and susceptible 
targets of ROS damage.  The abundance of mitochondria existing in heart could 
cause extensive production of ROS and exacerbate the ROS-induced tissue 
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damage, which is related to mitochondrial dysfunction (Hansen at al., 2006).  
Second, the heart has relatively lower amounts of antioxidant enzymes like SOD 
and catalase compared to other tissues, such as the liver (Gao et al., 2008).  In 
fact, after exposure to DOX, cardiomyocytes show a further decrease in the 
content/activity of antioxidant enzymes, including GPx, cytosolic Cu,ZnSOD and 
mitochondrial MnSOD, at least at some specific time points (Li et a., 2000). 
 
Current treatment for DOX induced cardiotoxicity 
    At present, there are three major approaches for primary prevention of DOX-
induced cardiotoxicity.  One strategy is to reduce cardiotoxic potency by 
administering DOX via continuous infusion instead of one bolus injection.  The 
idea behind this approach is that the DOX concentration in the heart is lower 
when a continuous infusion is given, leading to lower clinical cardiotoxicity, while 
DOX concentrations in tumor tissue are the same with continuous or bolus 
administration (Pacciarini et al., 1978).  Thus, increasing infusion duration clearly 
reduced cardiotoxicity without compromising oncological efficacy.  Another 
strategy is to use liposomal encapsulation, or using a less cardiotoxic derivative 
(e.g., epirubicin or idarubicin).  Liposomal DOX is trapped within the internal 
aqueous compartment by the ion gradient difference and helps to restrict DOX 
inside the vessel wall of organs with tight capillary junctions (normal tissues such 
as the heart), but allows DOX to more readily penetrate through tumor 
vasculature, which is more fragile and permeable than healthy tissue.  Thus, 
liposomal DOX can significantly decrease the DOX concentration in the heart 
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without impairment of its anti-cancer efficacy (Rahman et al., 2007; Safra et al., 
2000).  However, because of its high cost, liposomal DOX is not widely used yet.  
In addition to changing the way of administration and drug formulation, another 
approach to relieve DOX-induced cardiotoxicity is to use a cardioprotective agent 
in conjunction with DOX treatment.  Dexrazoxane is the only cardioprotective 
drug currently available in the clinic.  Dexrazoxane’s ability to chelate iron was 
previously thought to be the primary mechanism of cardioprotection.  However, 
the lack of similar effects when other even stronger iron chelators are used has 
questioned this mechanism (Simůnek et al., 2009).  Finally, because there is 
some concern that dexrazoxane may attenuate the chemotherapeutic efficacy of 
DOX, it is recommended that its use be initiated only after a patient has received 
more than 300 mg/m2 of DOX. 
   At present, scientists continue to identify additional optimal ways to address 
this problem, and some potential candidates are under investigation.  One major 
category is antioxidant chemicals and free radical scavengers.  For example, 
Carvedilol, a clinically approved adrenergic blocking agent with potent anti-
oxidant activity, has been found to be protective against DOX-induced ROS 
generation and apoptosis in rat heart in vivo (Oliveira et al., 2004).  Another 
antioxidant, probucol, has been shown to prevent the left ventriculal ejection 
fraction (LVEF) decrease in DOX-treated rats (Li et al., 2000; Lou et al., 2005; 
Singal et al., 2000).  However, while the animal model studies and in vitro 
experiments have generally shown the favorable effects of antioxidant therapy, 
the results of clinical studies of antioxidants in patients have been inconsistent 
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due to differences in the antioxidant agent used, timing of therapy, type of 
malignancy and chemotherapeutic regimen.  Continuous efforts in elucidating the 
pathogenic mechanisms, as well as identifying new therapeutic targets, will 
certainly be necessary for the development of more effective therapies. 
 
ATP-binding cassette (ABC) transporter superfamily 
   The ATP-binding cassette (ABC) transporter superfamily is one of the largest 
and most broadly expressed transmembrane protein superfamilies known.  The 
members are classified as ABC transporters based on the sequence and 
organization of their ATP-binding domain, also known as NBDs (nucleotide 
binding domains).  ABC transporters are ubiquitous integral membrane proteins 
and the vast majority of them utilize the energy of ATP hydrolysis to actively 
transport a wide variety of substrates across extra- and intracellular membranes.  
Their substrates include phospholipids, ions, peptides, steroids, polysaccharides, 
amino acids, organic anions, bile acids, drugs, and other xenobiotics (Linton et 
al., 2007; Higgins et al., 2001).  These transport activities are critical for most 
aspects of cell physiology and broadly impact human health and disease.  
Genetic variation in these genes is the cause or contributor to a wide variety of 
human disorders, including cystic fibrosis, neurological disease, retinal 
degeneration, cholesterol and bile transport defects, anemia, and drug response 
phenotypes (Mendoza et al., 2007; Leonard et al., 2003; Kim et al., 2009; 
Lambrechts et al., 2015).  
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ABC transporter subfamilies and structure 
    Phylogenetic analysis places the 48 known human ABC transporters into 
seven distinct subfamilies (ABCA through ABCG) (Table 1.1).  All ABC 
transporters share a common architecture comprising two hydrophilic nucleotide-
binding domains (NBDs) and two hydrophobic transmembrane domains (TMDs) / 
membrane spanning domains (MSDs) (Linton et al., 2007).   
    NBDs are located in the cytoplasm and each NBD contains three conserved 
domains: Walker A and Walker B motifs, found in all ATP-binding proteins, and a 
signature (C) motif, located just upstream of the Walker B site.  The C motif is 
specific to ABC transporters and distinguishes them from other ATP-binding 
proteins.  NBDs are the sites which bind and hydrolyze ATP and also are 
involved in coupling the energy released by binding and hydrolysis of ATP to 
processes of cross membrane transport.  TMDs are usually composed of at least 
six transmembrane (TM) α-helices.  They form the pathway through which solute 
crosses the membrane and also determine the specificity of the transporter 
through substrate-binding sites (Higgins et al., 2001; Linton et al., 2007).  
    Based on the position and orientation of membrane spanning segments and 
other domains (predicted by computer modeling and laborious biochemical 
experiments), there are three most plausible membrane topology models for the 
key ABC transporters.   As shown in Figure 1.2, ABCB1 (MDR1/Pgp) is a "full 
transporter" with six TM helices in both TMDs, each followed by an NBD.  A 
similar membrane topology has been predicted for ABCB4 (MDR3), ABCC4 
(MRP4), ABCC5 (MRP5), and ABCB11 (BSEP) as well.  In addition to an MDR1-
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like core, MRP1 contains an additional N-terminal segment of about 280 amino 
acids.  A major part of this region is membrane-embedded with five 
transmembrane helices (TMD0), while a small cytoplasmic loop of about 80 
amino acids (CL) connects this area to the core region.  Transporters with similar 
structure include ABCC2 (MRP2), ABCC3 (MRP3), and ABCC6 (MRP6).  The 
last category includes half-size transporters which have only one TMD fused to 
one NBD, for example, ABCG2 (BCRP) subfamily.  These transporters dimerize 
to form a biologically active ABC-transporter. 
 
Mechanisms of the transport process 
    ABC transporters are mostly unidirectional.  In bacteria, ABC transporters are 
predominantly involved in the import of essential compounds (sugars, vitamins, 
metal ions, etc.) into the cell, while in eukaryotes, most ABC transporters move 
compounds from the cytoplasm to the outside of the cell or into an intracellular 
compartment, such as endoplasmic reticulum, mitochondria, peroxisome (Saurin 
et al., 1999).  Despite the diversity of localization and substrate specificity, ABC 
transporters share a common basic mechanism of transport: two NBDs bind and 
hydrolyze ATP, and energize unidirectional substrate transport, which occurs 
through a translocation pathway provided by two MSDs. 
    For ABC transporters that efflux the substrate from mammalian cells, an ATP-
switch model (Higgins et al., 2004; Dong et al., 2005) is popularly used to explain 
this transport process in four steps (Figure 1.3). (a) The transport cycle is 
initiated by the interaction of substrate with the TMDs from the intracellular face 
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of the membrane.  (b) The substrate binding induces a conformational change in 
the TMDs, and this conformational change is transmitted to the NBDs to initiate 
binding of two molecules of ATP.  Basically, two NBDs interact with each other to 
form two composite nucleotide binding sites.  At each nucleotide binding site, one 
ATP molecule is sandwiched between the Walker A and Walker B motifs from 
one NBD and the LSGGQ ABC signature motif (C-motif) from the other NBD.  (c) 
ATP binding induces further conformational changes in the NBDs, which are 
transduced to the TMDs: a high-affinity substrate binding site at the inside of the 
membrane is reoriented to be exposed to the outside of the membrane.  
Simultaneously its affinity to substrate is reduced, resulting in extracellular 
release of the substrate.  (d) Finally, ATP hydrolysis causes the transporter to be 
reset and the binding site reoriented back to face the inside of the membrane and 
affinity restored.  It is clear that both NBDs are required, and both must hydrolyze 
ATP, and they do so by an ‘alternating catalytic cycle’ mechanism in which only 
one NBD hydrolyses one ATP at a time. 
 
ABC transporters in cancer and normal tissues 
    Overexpression of certain ABC transporters has been associated with 
chemotherapy resistance in many cancer types, like leukemia, breast cancer, 
lung cancer and ovarian cancer.  The mechanisms involved are revealed by 
biochemistry studies that demonstrate that some ABC transporters efflux 
cytotoxic drugs out of the cell, thus keeping intracellular drug concentrations 
below the cell-killing threshold.  These ABC transporters are called multidrug 
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resistant (MDR) proteins.  They include, but are not limited to, transporters such 
as P-glycoprotein (Pgp), MPR1, MRP2, and BCRP. 
    Although initially being found in drug resistance tumor cells, some ABC 
transporters are ubiquitously expressed in many normal tissues, including blood-
brain barrier, liver, kidney, placenta, etc.  Recently, there is a growing body of 
evidence showing the importance of ABC transporters in multiple normal organs’ 
defense, such as regulating central nervous system permeability, protecting 
testicular tissue and the developing fetus.  They are also involved in the toxin 
excretion from the liver, gastrointestinal tract and kidney, to protect the entire 
organism.  These protective roles are conducted mainly through the excretion of 
toxic compounds and their metabolites (Leslie et al., 2005; Fromm, 2004; Sarkadi 
et al., 2004).  
 
Multidrug resistance-associated protein 1 (MRP1/ABCC1)  
    Multidrug resistance-associated protein 1 (MRP1/ABCC1) is a member of the 
ABCC subfamily.  The murine (Mrp1) and human (MRP1) orthologues of MRP1 
are 88% identical.  MRP1 was first discovered in a drug-selected human small 
cell lung carcinoma cell line, H69AR, which had developed drug resistance to 
DOX without the increase in expression of Pgp (Cole et al., 1992).  MRP1 is a 
190 kDa heavily glycosylated ABC transporter that contains three TMDs and two 
NBDs.  The additional transmembrane domain TMD0, and the intra-cellular loop 
between TMD0 and TMD1, are important for trafficking and insertion of MRP1 in 
the plasma membrane (Westlake et al., 2005).  With extensive investigation in 
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past two decades, MRP1 has been demonstrated to play an important role in the 
development of drug resistance of various types of cancer (Hsia et al., 2002; 
Triller et al., 2006; Nooter et al., 1997a; Nooter et al., 1997b; Sullivan et al., 
1998).  It does not appear to play a significant role in the absorption or 
eliminations of drugs, but does seem to be an important modulator of drug tissue 
exposure and metabolite cellular elimination. 
 
MRP1 tissue distribution and intracellular localization  
    Beyond the tumor tissues, constitutive MRP1 is ubiquitously expressed in most 
normal tissues, especially in heart, skin, lung, brain capillary endothelial cells, 
and small intestine (Flens et al., 1996; Nies et al., 2004).  In polarized epithelial 
cells, MRP1 is usually found in the basolateral membrane.  While being primarily 
located in the plasma membrane, MRP1 is also found in the membrane of 
intracellular organelles such as endocytic vesicles, lysosomes located near the 
nucleus, trans-Golgi vesicles, and the mitochondria (Rajagopal et al., 2003; 
Gennuso et al., 2004; Jungsuwadee et al., 2009). 
 
Substrates of MRP1 
    MRP1 effluxes a wide range of endobiotics and xenobiotics (Figure 1.4).  
These substrates are usually amphiphilic anionic compounds, including 
glutathione (GSH) and glutathione disulfide (GSSG) as well as GSH, glucuronide 
and sulfate conjugated organic anions, such as leukotriene C4 (LTC4) and GS-
HNE (Leier et al., 1994; Cole and Deeley. 1998; Renes et al., 2000; Leslie et al., 
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2001; Jungsuwadee et al., 2012).  MRP1 also transports nonconjugated 
hydrophobic compounds in the presence of GSH, such as the natural product 
type chemotherapeutic agents Vinca Alkaloids and mutagens, such as aflatoxin 
B1 (Cole and Deeley., 2006).  
  
 MRP1 protects normal tissues against toxic effects of xenobiotics 
In normal polarized epithelial cells, MRP1 is usually found on the basolateral 
membrane, and thus may serve to efflux substrates into the bloodstream or 
interstitial space.  Generation and characterization of Mrp1-/- mice demonstrated 
that this protein is not essential for normal viability and fertility of mice (Wijnholds 
et al., 1997; Lorico et al., 1997).  However, these Mrp1-/- mice show impaired 
ability to transport some endobiotics and xenobiotics.  For example, Mrp1-/- mice 
are hypersensitive to the anticancer drug etoposide, and exhibit reduced 
inflammatory responses attributed to disrupted leukotriene homeostasis caused 
by the inability of these mice to efflux LTC4 (Wijnholds J et al., 1997).  Detailed 
analysis of the etoposide toxicity indicates that Mrp1 contributes to the protection 
of the oropharyngeal mucosal layer and the seminiferous tubules of the testis, 
and it appears very likely that normally Mrp1 restricts access of etoposide to 
these tissues (Wijnholds et al., 1998).   Mrp1-/- mice also show impairment in the 
efflux of [14C] grepafloxacin and Fluo 3 in the skin (Li et al., 2005).  In addition, a 
role for Mrp1 was demonstrated in cerebral amyloid-β (Aβ) clearance and brain 
accumulation, being identified as a potential target for treatment or preventing 
Alzheimer’s disease and cerebral amyloid angiopathy (Krohn et al., 2011).  Mrp1-
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/- mice are also hypersensitive to sodium arsenite, sodium arsenate, and 
antimony potassium tartrate (Rappa et al., 1997).  These data demonstrate that 
Mrp1 protects the normal tissues by effluxing endobiotics and xenobiotics and 
thus prevents the toxicants’ accumulation in cell or tissue.  However, it is largely 
unknown how Mrp1 functions in heart, especially when the heart is under stress, 
such as that induced by DOX treatment.  
 
Clinical association between genetic variants of MRP1 and anthracycline 
induced cardiotoxicity 
    Genetic variations at the level of single nucleotide polymorphisms (SNPs) are 
well demonstrated to be associated with the differences of disease susceptibility 
and therapy response among the population.  More recently, inter-individual 
difference in genes encoding the drug transporters have received considerable 
attention because of their ability to contribute to differences in drug absorption, 
distribution, and elimination that ultimately affect both drug efficacy and toxicity 
(Cole, 2014a).  Accumulating case-control clinical studies have shown that 
several MRP1 SNPs are associated with the susceptibility to cardiotoxicity 
observed in cancer patients treated with anthracycline (Table 1.2) (Wojnowski et 
al., 2005; Semsei et al., 2012; Visscher et al., 2012).  Although the biological 
function of these SNPs are not fully understood, we expect these SNPs could 
potentially change the expression and function of MRP1 and further impair the 
efflux of substrates, and finally contribute to the susceptibility to DOX-induced 
cardiotoxicity.   Prior studies by our laboratory focused on one of these SNPs 
18 
 
(Gly671Val).  Our laboratory demonstrated that HEK cells that overexpress 
MRP1 (Gly671Val) are more sensitive to DOX toxicity compared to cells that 
overexpress WT MRP1.  Although human MRP1 can efflux DOX, this mutant 
MRP1 does not significantly increase the intracellular concentration of DOX in 
HEK cells, but impaired by more than 85% MRP1’s activity in effluxing GS-HNE, 
which is an important toxic metabolite of lipid peroxidation (Jungsuwadee et al., 
2012).  This implies that MRP1 could play an important role in heart defense 
against DOX toxicity by effluxing toxic substrates other than DOX.  Here, we will 
focus on MRP1’s substrates that are related to oxidative stress.  
 
Oxidative stress  
Oxidative stress refers to a harmful condition that occurs when there is an 
excess of ROS, a failure of antioxidant defense systems, or both (Sies, 1997; 
Dasuri et al., 2012).  ROS include free radicals, such as •O2
- and •OH, and 
nonradicals capable of generating free radicals, such as H2O2.  These ROS can 
be derived from several intracellular sources, including mitochondria, NAD(P)H 
oxidase, xanthine oxidase, and uncoupled nitric oxide synthase, as well as from 
exogenous factors such as DOX exposure.  To protect cells from the damage 
caused by ROS, organisms have evolved a variety of antioxidant systems to 
rapidly and efficiently remove ROS or inhibit their activities and maintain 
appropriate redox homeostasis (Figure 1.5).  The main antioxidant enzymes 
include superoxide dismutase (SOD), catalase, glutathione peroxidase (GPx), 
peroxiredoxin (Prx) and glutathione S-transferase (GST).   SOD converts two 
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•O2
- into one molecule of H2O2 and one molecule of O2, while catalase further 
catalyzes the decomposition of H2O2 into H2O and O2.  The main reactions that 
GPx and Prx catalyze are to reduce H2O2 to H2O by consumption of reduced 
GSH or reduced thioredoxin (Trx). In addition to these antioxidant enzymes, 
there are also small antioxidant molecules such as GSH, peroxiredoxin (Prx), 
thioredoxin (Trx), vitamin C, and vitamin E.  Oxidative stress has been implicated 
in numerous diseases at multiple organs, while heart is particularly vulnerable to 
oxidative stress induced damage due to relatively low expression/activity of 
antioxidant enzymes, and the low regeneration ability of the highly differentiated 
cardiomyocytes.  Here, this dissertation mainly focuses on GSH/GSSG 
homeostasis and the lipid peroxidation product 4-Hydroyx-2-nonenal (HNE), 
because GSH, GSSG and GS-HNE are all substrates of MRP1.   
 
GSH and GSSG homeostasis in cells  
    GSH is a tripeptide - γ-glutamyl-cysteinyl-glycine with a gamma peptide 
linkage between the carboxyl group of the glutamate side chain and the amine 
group of cysteine, which is attached by normal peptide linkage to a glycine.  
Reduced GSH is the most abundant intracellular non-protein thiol in almost all 
aerobic species.  Due to its cysteinyl moiety, GSH is a nucleophile that provides 
electrons to electrophilic species to form GSSG.  GSSG can be catalytically 
reduced back to GSH by the NAD(P)H dependent GSH reductase (GR) (Figure 
1.6).  The continued function of the redox cycle activity is dependent on the 
availability of NADPH, of which the pentose phosphate pathway is a major 
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source (Lushchak, 2012).  Under physiological conditions, reduced GSH is the 
major form, with its concentration from 10 – 100 fold higher than the oxidized 
form, present as mixed disulfide (mainly GS-S-protein) and the disulfide (GSSG).  
However, this ratio will decrease in the presence of ROS, due to the rapid 
oxidation from GSH to GSSG.  Therefore, the GSH/GSSG ratio is an important 
indicator of the redox environment.  Maintenance of GSH homeostasis plays a 
vital role in a multitude of cellular processes, including drug and free radical 
detoxification, cell differentiation, proliferation and apoptosis (Jones, 2008).  
    In addition to its role in elimination of ROS, GSH is also a signaling molecule.  
It is added to proteins as a post-translational modification (Pompella et al., 2003) 
to form S-glutathionylated proteins.  It interacts with nitric oxide (NO) to modify its 
bioavailability (Hogg et al., 2002).  It also modifies the activity of neurotransmitter 
receptors and may itself be active as a neurotransmitter (Oja et al., 2000).  In 
conclusion, GSH is a multifunctional molecule with diverse and still emerging 
functions. 
 
GSH synthesis and metabolism 
    GSH is synthesized in all mammalian cells, and the liver is a major site.  The 
synthesis from the precursor amino acids cysteine, glutamate and glycine is 
accomplished by a consecutive action of two ATP-dependent enzymes (Figure 
1.7).  First, gamma-glutamate-cysteine ligase (GCL), a heterodimer of a catalytic 
subunit (GCLc) and a modulatory subunit (GCLm), forms an unusual peptide 
bond between the γ-carboxyl of glutamate and the amino group of cysteine using 
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the energy provided by the hydrolysis of ATP (Lu, 2013).   This is the rate-limiting 
step of GSH synthesis in vivo.  The second step is addition of glycine to γ-
glutamylcysteine.  This reaction is catalyzed by glutathione synthase (GSS) and 
driven by the hydrolysis of another ATP.  After its synthesis, GSH is delivered to 
some intracellular compartments, including mitochondria, endoplasmic reticulum, 
nucleus, and to the extracellular space (e.g., blood plasma and bile) for utilization 
by other cells and tissues (Forman et al., 2004). 
    The overall rate of GSH synthesis is controlled by several factors, including: (i) 
availability of the substrate, mainly L-cysteine.  This is determined by membrane 
transport activities of the three sulfur amino acids cysteine, cystine and 
methionine, and the conversion of methionine to cysteine via the trans-sulfuration 
pathway (Grimble et al., 1992); (ii) the activity of the rate-limiting enzyme - GCL. 
This is determined by the expression level and relative ratio between its two 
subunits GCLc and GCLm (Chen et al., 2005).  In most tissues, GCLc is found in 
excess compared to GCLm, while the binding of GCLc to GCLm dramatically 
decreases the sensitivity of the holoenzyme to GSH inhibition, presumably by 
changing the conformation of the enzyme; (iii) extent of feedback inhibition of 
GCL, especially GCLc by GSH (Taylor et al., 1996).  Additionally, in some cases, 
the provision of ATP for GSH synthesis could represent another limiting factor.  It 
is worth noting that both GCL and GS are sensitive to oxidative stress, and their 
expression is mainly under the regulation of the Nuclear factor (erythroid-derived 
2)-like 2 (Nrf2), a transcription factor that regulates a wide array of antioxidant 
responsive element-driven genes in various cell types (Lu, 2009).  
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    Although GSH is synthesized intracellularly in all the cell types, its 
biodegradation occurs outside of cells (Figure 1.8).  Since GSH is not susceptible 
to proteolysis due to its unusual γ–carboxyl peptide linkage, GSH is resistant to 
intracellular degradation and its degradation only occurs in cell types that have 
gamma-glutamyl transpeptidase (γGT), an ectoenzyme on the cell membrane.  
γGT removes the γ–glutamyl moiety from GSH under physiological conditions, 
and then dipeptidase removes the glycyl moiety (Ballatori et al., 2009).  The 
breakdown products (glutamate, glycine, and cysteine) can be taken up into the 
cell for GSH synthesis.  In yeast, an alternative pathway of GSH degradation is 
mediated by a novel cytosolic protein complex involving three new genes Dug1, 
Dug2 and Dug3 (Ganguli et al., 2007; Baudouin-Cornu et al., 2012).   
 
MRP1 and GSH/GSSG homeostasis 
The relationship between GSH and MRP1 is complex.  On one hand, GSH 
influences MRP1’s ATP-dependent transport activity by either its direct 
conjugation to the substrates or binding MRP1 and stimulating its transport 
activity.  On the other hand, MRP1 is able to efflux GSH directly (Cole, 2014b).  
GSH itself is a low affinity substrate of MRP1 (Km = 1-5 mM), but it is a suitable 
substrate for MRP1 under physiological conditions, considering that the 
physiological concentration of GSH is in the mM range in most cells.   Co-
transport of GSH with another substrate is another mechanism of GSH transport 
through MRP1. For example, depleting GSH with BSO inhibits transport of 
daunorubicin, vincristine, and aflatoxin B1 (Versantvoort et al., 1995; Rappa et al., 
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1997; Salerno and Garnier-Suillerot, 2001).  In addition, the ability of MRP1 to 
transport GSH can be markedly enhanced in vitro by a variety of xenobiotics (e.g., 
verapamil, vincristine, the antivirals indinavir and nelfinavir), including 
bioflavonoids (e.g., apigenin) (Loe et al., 2000; Cole., 2014b). 
    Whereas the role of GSH in preventing oxidative stress is well understood, the 
precise dynamics of MRP1 in regulating cellular GSH levels require clarification.  
It has been observed that the GSH content in cells overexpressing MRP1 is 
much lower than that of control cells, while Mrp1-/- mice have increased basal 
levels of GSH in multiple tissues (Rappa et al., 1997; Wijnholds et al., 1997). 
Minich et al (2006) also reported that astrocytes isolated from Mrp1-/- mice have 
50% more intracellular GSH.  Further, inhibiting MRP1 or selectively knocking 
down MRP1 causes a decrease in GSH release in both unstressed and stressed 
conditions (Minich et al., 2006; Sreekumar et al., 2012).  This means that the 
basal intracellular level of GSH is affected by its efflux through MRP1.  This is 
further demonstrated by the observation that the basal level of GSH export in 
Mrp1-/- mice stem cells is approximately one half of that observed in wild type 
cells (Cole et al., 1990; Rappa et al., 1997).  The MRP1-mediated GSH transport 
in different cell types in specific tissue/organ has also received considerable 
attention.  For example, in the brain, astrocytes maintain the redox balance of the 
cellular milieu by the MRP1-mediated extrusion of GSH (Minich et al., 2006).   
    In addition to GSH, GSSG has also been shown to be effluxed across the 
plasma membrane through MRP transporters (Hirrlinger et al., 2001; 2005; 
Minich et al., 2006; Cole and Deeley, 2006).  As discussed above, GSSG tends 
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to accumulate in cells under conditions of oxidative stress.  Because of its 
deleterious pro-oxidant activities, maintenance of low levels of GSSG (and an 
appropriately low GSSG/GSH ratio) is important for normal cellular function.  This 
maintenance is accomplished mostly by a combination of the reduction of GSSG 
back to GSH by GR and the efflux of GSSG by MRP1 (and MRP2).  MRP1’s 
affinity for GSSG (Km ∼100 μM) is significantly higher than that for GSH (Km ∼ 1-
5 mM) (Cole SP et al, 2006).  MRP1-mediated GSSG efflux occurs during 
oxidative stress in several cell types, including astrocytes and endothelial cells 
(Minich et al., 2006; Ellison and Richie et al., 2012).  A recent study implicates 
MRP1 as a neuroprotective factor against stroke and attributes this ability to 
MRP1-mediated efflux of GSSG, a known trigger of neuronal cell death (Park et 
al., 2011).  These data indicate the role of MRP1 in the cellular response to 
oxidative stress.  Thus, loss of MRP1 influences the intracellular level of GSH 
and GSSG, may disrupt the balance of the GSH/GSSG redox couple, and finally 
impair normal tissues’ ability to defend against oxidative stress-induced injury.  
 
Lipid peroxidation  
    The free radical-mediated peroxidation of lipids has received a great deal of 
attention in connection with oxidative stress in vivo.   Free radicals, for example 
hydroxyl radical (OH·) generated from H2O2 via the Fenton– and Haber–Weiss 
reactions, mediate the removal of a hydrogen atom (H•) from a lipid (LH), which 
yields a lipid radical (L•).   In the propagation phase, L• reacts with O2 and forms 
a lipoperoxyl radical (LOO•), which in turn reacts with another polyunsaturated 
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fatty acids (PUFA) to yield a new L• and a lipid hydroperoxide (LOOH) (Figure 
1.9A).  Thus, one free radical can generate a high number of lipid hydroperoxides 
until the chain reaction is terminated by a chain-breaking antioxidant.  Lipid 
peroxidation has been implicated in various diseases and aging, including 
inflammation, atherosclerosis, cataract formation, chronic degenerative diseases 
of the nervous system, and chronic liver disease (Sultana et al., 2013; Yadav et 
al., 2013; Parola et al., 1996).   
 
HNE formation 
    Since lipid hydroperoxides (LOOH) produced by the chain reaction of lipid 
peroxidation are unstable, they decompose to various secondary products of lipid 
peroxidation, including malondialdehyde (MDA) and HNE (Figure 1.9B).  The 
physiological concentration of HNE is in the submicromolar range (<0.1 μM), 
while in oxidative stress, even micromolar levels can be observed (Esterbauer et 
al., 1991; Butterfield and Stadtman, 1997).  Thus, HNE can be regarded as a 
biomarker of oxidative stress. 
    HNE is very hydrophobic, so that it is mostly associated with the membranes 
where it is produced from the peroxidation of arachidonic and linoleic acids. 
Since HNE is relatively stable, it can diffuse remarkable distances from the site of 
formation to different cellular compartments.  It has three main functional groups: 
an aldehyde, a double bond (alkene) between carbon C2 and C3, and a 
secondary alcohol at carbon C4 (Figure 1.10).  HNE is a highly electrophilic 
molecule that easily reacts with glutathione, proteins and, at higher 
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concentrations, with DNA.  HNE reacts with cysteine, histidine, and lysine 
residues of proteins, likely resulting in functional impairment (Esterbauer et al. 
1991) (Figure 1.11).   
    To protect macromolecules from modification or adduction by HNE, 
mammalian cells metabolize 4-HNE rapidly (Figure 1.12).  One important 
pathway of detoxification is through conjugation with GSH, either spontaneously 
or through GSH-S-transferases  (GST) to form GS-HNE, which must be effluxed 
to alleviate intracellular toxicity (Volkel et al., 2005).  In addition, HNE metabolism 
includes reduction to the corresponding alcohol, 1,4-dihydroxy-2-nonene (DHN) 
or oxidation to the corresponding acid, 4-hydroxy-2-nonenoic acid (HNA) (Alary 
et al., 2003; Volkel et al, 2005).   GS-HNE can also be metabolized via an NADH-
dependent alcohol dehydrogenase (ADH)-catalyzed reduction to GS-DHN and/or 
aldehyde dehydrogenase-catalyzed oxidation to GS-HNA.  The biological 
activities of these GSH conjugates are not yet well characterized. 
 
MRP1 and HNE detoxification 
As discussed above, the GSH/GST system is a well-known mechanism in the 
cellular defense against oxidative stress.  The excretion of GSH conjugates is 
important in decreasing intracellular concentrations of toxins because 
conjugation reactions can be reversible.  In addition, some metabolites become 
more toxic on conjugation with GSH.   
    The conjugation of HNE with GSH forms a less toxic metabolite, GS-HNE, but 
its accumulation inside the cell can still generate toxicity due to end-product 
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inhibition of relevant GST, with subsequent accumulation of HNE and ensuing 
toxicity (Diah et al., 1999; Renes et al., 2000).  Thus, the extrusion of GS-HNE is 
required for preventing these adverse toxicities.  Evidence for a significant role of 
MRP1 as a transmembrane efflux transporter for GS-HNE conjugates has been 
reported, and the Km is in the µM range.  In a human small cell lung cancer cell 
line, the expression of MRP1 was associated with protection against HNE toxicity 
(Renes et al., 2000).  Our laboratory reported that mutant MRP1 (Gly671Val) 
impaired MRP1’s ability to efflux GS-HNE by more than 80%, and caused a 
higher sensitivity to DOX toxicity in HEK cells (Jungsuwadee et al., 2012).  That 
study also found that HNE-adducted protein is increased in mouse heart after 
DOX treatment and that sarcolemmal membrane vesicles from Mrp1-/- mice are 
unable to transport GS-HNE, indicating that Mrp1 is the only ATP-dependent 
efflux transporter in the mouse heart (Jungsuwadee et al., 2006).  Thus, 
understanding of MRP1’s effects on GS-HNE efflux and intracellular GS-HNE 
accumulation are needed to clarify the potential role of MRP1 in normal heart 
tissue defense against oxidative stress.  
 
Research Objectives 
    This study explored the potential protective function of Mrp1 in DOX-induced 
cardiotoxicity.  Mrp1-/- mice and their WT littermates were used as a study model. 
Although Mrp1 is highly conserved between human and rodents with 88% 
sequence homology, the human isoform (MRP1) is able to transport DOX, 
whereas murine Mrp1 has only a negligible ability to transport this anthracycline 
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(Stride et al., 1997).  Therefore, the Mrp1-/- mouse provides a good model to 
study the role of Mrp1 in DOX cardiotoxicity separately from the effects of DOX 
retention.  Of course, the diiference of human MRP1 and murine Mrp1 regarding 
the efflux of DOX could limite the translation from experimental finding in mouse 
model to clinical research.    
    In this study, after giving the mice chronic DOX treatment, the left ventricle 
function, heart apoptosis and heart fibrosis were evaluated.  Effects of Mrp1 on 
DOX cytotoxicity were also investigated in two major cell components of heart: 
neonatal mouse cardiomyocytes and neonatal cardiac fibroblasts, including the 
effects on cell survival, cell apoptosis, and DNA damage.  The mechanisms of 
Mrp1-mediated protection were further investigated based on known functions of 
Mrp1, mainly focusing on glutathione homeostasis, GS-HNE accumulation, and 
protein oxidative damage.     
    The results of the current study demonstrate that Mrp1 protects mouse heart 
against DOX-induced cardiotoxicity.  Clinical studies show an association 
between multiple genetic variants of MRP1 gene and cancer patients’ 
susceptibility to DOX induced cardiotoxicity.  Thus, our study may provide 
explanations for these clinical observations if any SNPs impair MRP1’s 
expression or activity.  It will further help to identify these susceptible patients 
and modify chemotherapy strategies for them, and thus prevent such drug-
induced toxicity.  
    This dissertation research was conducted to test the following hypotheses: 
1.  Loss of Mrp1 will potentiate chronic DOX-induced cardiac dysfunction in mice; 
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2. Loss of Mrp1 will sensitize cardiomyocytes and/or cardiac fibroblasts to DOX 
cytotoxicity; 
3.  GSH/GSSG homeostasis will be disrupted in Mrp1-/- mouse heart.  
4. Loss of Mrp1 will cause GS-HNE accumulation in mouse heart tissue after 
DOX administration. 
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Figure 1.1. Schematic illustration of redox cycling of DOX.  The quinone 
moiety of DOX accepts one electron from NAD(P)H to form a semiquinone that 
quickly regenerates its parent quinone by reducing oxygen to form superoxide 
(•O2
-);  NAD(P), nicotinamide adenine dinucleotide (phosphate); •O2
-, superoxide 
(Stěrba et al., 2013) 
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Figure 1.2. Structures of three categories of ABC transporters.  Schematic 
representation of the predicted domain arrangement of (A) full length transporter; 
(B) extended full length transporters with an extra transmembrane domain at the 
N-terminus (TMD0), and (C) half transporters that require dimerization for full 
function.   ABC, ATP-binding cassette; CL, cytoplasmic loops. 
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Figure 1.3. Proposed transport mechanism of ABC transporters.  (a) 
Substrates interact with the TMDs from the intracellular face of the membrane.  
(b) TMDs undergo a conformational change and 2 molecules of ATP bind to the 
NBDs.  (c) ATP binding induces further conformational changes of TMDs, 
resulting in substrate translocation.  (d) ATP hydrolysis and transporter is reset 
for substrate binding.  TMD, transmembrane domain; NBD, nucleotide-binding 
domains.  (Dong et al., 2005) 
 
 
 
(a) (b) (c) (d) 
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Figure 1.4. Substrates of MRP1.  Shown are representative examples of the 
endo- and xenobiotics (and organic anion metabolites) effluxed from cells by 
MRP1 in either a glutathione (GSH)-independent or GSH-dependent manner. 
MRP1 can transport glutathione, glucuronide or sulfate conjugated organic 
anions (COA) (2) and unconjugated organic anions (UCOA) (1).  (3)  MRP1 also 
co-transports GSH and substrates.  (4) Some MRP1-mediated COA transport is 
dependent upon the presence of GSH or its nonreducing derivative, S-
methylGSH.  (5) In addition, GSH transport is stimulated by the presence of 
drugs that are not themselves transported by MRP1.  4-HNE-SG, GSH conjugate 
of 4-Hydroyx-2-nonenal (GS-HNE); AFB1-SG, GSH conjugate of aflatoxin B1-
epoxide; COA, conjugated organic anion; E217βG, 17β-estradiol 17-(β-D-
glucuronide); EA-SG, GSH conjugate of ethacrynic acid; GS-NO, S-
nitrosoglutathione; GSSG, glutathione disulfide; LPI, lysophosphatidylinositol; 
(1) (2) (3) (4) (5) 
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LTC4, leukotriene C4; NNAL-OGluc, β-O-glucuronide conjugate of 4-
(methylnitrosamino)-1-(3-pyridyl)-1-butanol; PGA2-SG, GSH conjugate of 
prostaglandin A2; PGJ2-SG, GSH conjugate of 15-deoxy-12,14-prostaglandin J2; 
pHAA-SG, GSH conjugate of acetaminophen; QO-SG, GSH conjugate of 4-
nitroquinoline 1-oxide; S-1-P, sphingosine 1-phosphate; S-MeGSH, S-methyl 
GSH; UCOA, unconjugated organic anion.  (Cole, 2014b) 
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Figure 1.5. Redox signaling.  When •O2
- is formed, SOD converts two •O2
- into 
one molecule of H2O2 and one molecule of O2.  Catalase catalyzes the 
decomposition of H2O2 into H2O and O2.  GPx and Prx reduce H2O2 to H2O by 
consumption of reduced GSH or reduced thioredoxin (Trx).  Grx are oxidized by 
substrates, and reduced non-enzymatically by GSH.  Gpx, glutathione 
peroxidase; GR, glutathione reductase; Grx, glutaredoxin; Prx, peroxiredoxin; 
SOD, superoxide dismutase; Trx, thioredixin; TrxR, thioredoxin reductase.  
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Figure 1.6. Redox cycling maintains cellular GSH/GSSG homeostasis 
during oxidative challenge.  Under oxidative stress, GSH detoxifies ROS to 
form GSSG.   The regeneration of GSH from GSSG is maintained by the GSSG 
reductase system in a NAD(P)H dependent manner.  GR: glutathione reductase; 
GPx: glutathione peroxidase. 
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Figure 1.7.  Process of GSH synthesis.  (A) In the first step of GSH synthesis, 
an amide linkage is formed between cysteine and glutamate catalyzed by the 
GCL.  (B) Then, GSS catalyzes the reaction between glycine and the cysteine 
carboxyl of γ-glutamylcysteine dipeptide to form GSH.  GCL, γ-glutamate-
cysteine ligase; GSS, glutathione synthetase. 
 
 
 
 
 
 
 
 
B 
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Figure 1.8. GSH degradation.  GSH is transported out of the cell and broken 
down by the membrane-bound ectoenzyme γGT, which removes the γ-glutamyl 
moiety, and then by dipeptidases, which remove the glycine moiety.  The 
resulting amino acids can be taken up by the cell and used for additional GSH 
synthesis.  ATP, adenosine triphosphate; ADP, adenosine diphosphate; Cys, 
cysteine; Glu, glutamate; Gly, glycine; Pi, inorganic phosphate; γGT, γ glutamyl 
transpeptidase. (Wang and Ballatori, 1998) 
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                                                   1. LH + X•               L• + XH  
                                                   2. L• + O2               LOO•  
                                                   3. LOO• + LH               LOOH + L• 
 
 
Figure 1.9. Oxidative stress causes lipid peroxidation and HNE formation.  
(A) Chain reaction of lipid peroxidation; (B) HNE is generated as a secondary 
product of lipid peroxidation. HNE, 4-Hydroyx-2-nonenal; MDA, malondialdehyde; 
PUFA, polyunsaturated fatty acids; RNS, reactive nitrogen species; ROS, 
reactive oxygen species.  
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Figure 1.10. Three main functional groups of HNE: an aldehyde, a double 
bond (alkene) between carbon C2 and C3, and a secondary alcohol at carbon C4. 
 
 
 
Figure 1.11. A linear depiction of HNE adducts with amino acids. HNE 
adduction can take place by the 1,4-addition (Michael addition) of the 
nucleophilic groups in cysteine (Cys), histidine (His) or lysine (Lys) residues of 
the protein, respectively, onto the electrophilic double bond of HNE, giving an 
increase in the protein's molecular mass by 156 Da with each molecule of HNE 
being added.   
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Figure 1.12. Metabolism pathways of HNE.  ADH, alcohol dehydrogenase; 
ALDH, Aldehyde dehydrogenase; AR, alcohol reductase; DHN, 1,4-dihydroxy-2-
nonene; GS-HNE, glutathione conjugate of 4-Hydroyx-2-nonenal; GS-DHN, 
glutathione conjugate of 1,4-dihydroxy-2-nonene; HNA, 4-hydroxy-2-nonenoic 
acid; HNE, 4-Hydroyx-2-nonenal. (Pappa et al., 2003) 
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Table 1.1: Human ABC transporters subfamilies 
Family Members Functions 
ABCA ABCA1 to ABCA12 Cholesterol efflux, phosphatidyl choline efflux, N-retinylidiene-PE efflux 
ABCB ABCB1 to ABCB11 Peptide transport, iron transport, Fe/S cluster transport, bile salt transport, 
xenobiotics transport 
ABCC ABCC1 to ABCA13 Organic anion efflux, nucleoside transport, chloride ion channel, sulfonylurea 
receptor, potassium channel regulation, xenobiotic transport 
ABCD ABCD1 to ABCD 4 Very long chain fatty acids transport regulation 
ABCE ABCE 1 Elongation factor complex 
ABCF ABCF1 to ABCF3 Unknown function 
ABCG ABCG1 to ABCG 5 Cholesterol transport, sterol transport, toxin transport 
4
2
 
 Table 1.2: SNPs of Mrp1 correlated with anthracycline induced cardiotoxicity 
Rs# Mutation  
(position) 
Location  
Type 
Disease 
Treated 
Drug Effect Ref 
rs45511401 2012 G>T 
(nsSNP) 
Gly671Val 
Exon 16 (NBD1) 
Non-Hodgkins 
lymphoma 
Doxorubicin cardiotoxicity Wojnowski et 
al., 2005 
rs3743527 C>T 3’-UTR ALL (childhood) Doxorubicin cardiotoxicity Semsei et al., 
2012 
rs246221 825 T>C Val275Val 
Exon 8 
ALL (childhood) Doxorubicin cardiotoxicity Semsei et al., 
2012 
rs4148350 G>T intron 15 Pediatric cancer Anthracycline cardiotoxicity Visscher  
et al., 2012 
ALL, Acute lymphoblastic leukemia; Rs#, reference SNP ID number. 
 
 
 
 
 
 
Copyright © Wei Zhang 2015 
4
3
 
44 
 
Chapter Two 
 
Loss of Mrp1 potentiates DOX-induced cardiotoxicity in mice 
 
Overview of Study 
Cardiotoxicity is one of the most severe side effects caused by anti-cancer 
chemotherapy, including DOX.  Previously our laboratory reported that 
expression of Mrp1 in cardiac sarcolemma increases in response to a single 
injection of DOX in mice (Jungsuwadee et al., 2006).  Our laboratory also 
reported that a single intravenous administration of DOX caused significantly 
higher nuclear injury in Mrp1-/- mice heart compared to their WT littermates.  In 
this chapter, experiments were conducted to investigate the effects of chronic 
DOX-induced cardiotoxicity in WT and Mrp1-/- mice and confirmed our prior 
finding in mice treated acutely with DOX, and more importantly, demonstrated 
the role of Mrp1 in protecting against DOX-induced cardiac dysfunction.  The 
health condition of these mice was monitored.  Chronic DOX caused body weight 
loss and hemotoxicity, and these adverse effects were significantly exacerbated 
in Mrp1-/- vs WT mice.  Using transthoracic echocardiography techniques, it was 
found that DOX caused more severe left ventricle dysfunction in Mrp1-/- mice, 
shown as significantly lower fractional shortening (FS) and ejection fraction (EF).  
This pathological dysfunction was consistent with the measurements of heart 
apoptosis and BNP expression in heart ventricle.  This study is the first to 
demonstrate the protective effects of Mrp1 against chronic DOX-induced cardiac 
dysfunction. 
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Introduction 
    Doxorubicin (DOX) is an effective chemotherapeutic anthracycline used for a 
variety of solid tumors and hematologic malignancies; however, its clinical use is 
significantly limited by its dose-dependent cardiotoxicity (Minotti et al., 2004; 
Octavia et al., 2012).  The incidence of cardiomyopathy is 2.5 times higher in 
cancer patients treated with DOX than that in untreated patients (Dolye et al., 
2005).  It is well-established that the reactive oxygen species (ROS) generated 
by DOX, which cycles between the quinone and semiquinone in cardiac 
mitochondria, contribute significantly to cardiac pathology (Yen et al., 1996; 
Gewirtz, 1999; Minotti et al., 2004).  However, the self-regulation and defense 
mechanisms of heart tissue in this process are still unclear.  
Multidrug resistance-associated protein 1 (MRP1/ABCC1), a member of the 
ATP-binding cassette (ABC) transporter protein superfamily, is ubiquitously 
expressed in multiple tissues, including heart (Flens et al., 1996; Nies et al., 
2004).  Mrp1 mediates the efflux of glutathione (GSH) and glutathione disulfide 
(GSSG) as well as GSH, glucuronate and sulfate conjugated organic anions, 
including leukotriene C4 (LTC4) and the GSH conjugate of 4-Hydroxy-2-nonenal 
(GS-HNE) (Leier et al., 1994; Cole and Deeley, 1998; Renes et al., 2000; Leslie 
et al., 2001; Jungsuwadee et al., 2012).  Although Mrp1-/- mice have normal 
fertility and viability, their ability to transport key endo- and xenobiotics is 
compromised (Wijnholds et al., 1997, Yoshioka et al., 2009).  
Accumulating case-control clinical studies have shown that several single-
nucleotide polymorphisms (SNPs) of MRP1 gene are related to susceptibility to 
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cardiotoxicity observed in cancer patients treated with anthracyclines, including 
DOX (Wojnowski et al., 2005; Semsei et al., 2012; Visscher et al., 2012).  These 
SNPs may affect efflux of DOX itself, but also may modulate efflux of other 
important endobiotics (Jungsuwadee et al., 2012).  Thus, MRP1 could play an 
important role in regulation of oxidative stress by effluxing GSH and GSSG as 
well as GS-HNE (Cole, 2014a; Cole, 2014b; Jungsuwadee et al., 2012).  
    In the present study, we explored the effects of Mrp1 on DOX-induced 
cardiotoxicity in mice.  Although Mrp1 is highly conserved between human and 
rodents with 88% sequence homology, the human isoform (MRP1) is able to 
transport DOX, whereas murine Mrp1 has only a negligible ability to transport this 
anthracycline (Stride et al., 1997).  More specifically, a glutamic acid, which has a 
negative charge, on TM14 in human MRP1 is critical to accomplish the transport 
of DOX.  This glutamic acid is substituted by a glutamine in murine Mrp1, with 
loss of the negative charge, and also loss of the ability to transport DOX (Figure 
2.1) (Zhang et al., 2001).  Therefore, the Mrp1-/- mouse provides a good model 
to study the role of Mrp1 in DOX cardiotoxicity separately from the effects of DOX 
retention.  Here evidence is presented for the first time that chronic DOX 
treatment caused more severe cardiac dysfunction in Mrp1-/- mice.  These 
results provide novel insights into the role of Mrp1 in cardiac protection beyond 
the ability to transport DOX. 
Materials and methods  
Animals and treatment 
C57BL/6 (WT) mice and Mrp1-disrupted C57BL/6 (Mrp1-/-) mice, initially a 
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gift from Dr. Gary Kruh, were backcrossed for more than ten generations, 
littermates bred in-house and maintained in the Division of Laboratory Animal 
Resources.  All experiments complied with the requirements of the Institutional 
Animal Care and Use Committee of the University of Kentucky (Lexington, KY).  
The animal treatment protocols were based on studies demonstrating decreased 
cardiac function following chronic treatment with DOX (Zhang et al., 2009).  All 
experiments used male mice 10 to 12-weeks old and weighing 25–35 g.  DOX 
(Pfizer, NY) was administered intraperitoneally at a dose of 3 mg/kg (Figure 2.2 
protocol A) or 2 mg/kg (Figure 2.2 protocol B) body weight, or an equivalent 
volume of saline, twice a week for 3 or 5 weeks, resulting in a cumulative DOX 
dose of 18 (Protocol A) or 20 mg/kg (Protocol B).  Hydration and nutritional gel 
(72-07-5022, ClearH2O, Portland, ME) were provided to mice as supplements, 1 
oz per 5 mice, and replaced every 2 days, in addition to pelleted food and water 
throughout the treatment period.  Animal body weight was recorded throughout 
the experimental period.  Animals were euthanized and examined 48 h or 2 
weeks after the last DOX treatment.   
 
Complete blood count 
Peripheral blood (∼20 µL) was collected from WT and Mrp1-/- mice 48 h and 
2 weeks after the last DOX treatment (Protocol B) by sub-mandibular bleeding.  
Blood cell parameters were obtained on the Hemavet 950FS automated 
hematology analyzer (Drew Scientific, Dallas, TX). 
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Transthoracic Echocardiography 
Transthoracic echocardiography was performed with a Vevo 2100 High-
Resolution In Vivo Imaging System (Visual Sonics Inc., Toronto, Canada).  The 
mice were lightly anesthetized by isoflurane (0.5-1.5%) until the heart rate 
stabilized at ~500 beats/min.  With the use of the M-mode from parasternal short-
axis images, left ventricular end-diastolic dimension (LVIDs) and left ventricular 
end-systolic dimension (LVIDs) were measured.  The percentage of left 
ventricular fractional shortening (LVFS) was calculated as 100 X ((LVIDd-
LVIDs)/LVIDd).  LV volume at end-diastole (LVEDV) was estimated as [7.0/(2.4 + 
LVIDd)] X LVIDd3 and at end-systole (LVESV) as [7.0/(2.4 + LVIDs)] X LVIDs3.  
Left ventricular ejection fraction (LVEF) was determined by using [(LVEDV - 
LVESV)/ LVEDV] X 100%.  Echocardiography was conducted by investigators 
who were blinded to treatment group assignments and genotype. 
 
Terminal Deoxynucleotidyl Transferase dUTP Nick End Labeling (TUNEL) 
assay 
    The tip of the mouse heart ventricle was fixed in 10% formalin, embedded in 
paraffin, 4 μm sections cut and stained using the ApopTag® Peroxidase In Situ 
Apoptosis Detection Kit (S7100, Millipore) according to the manufacturer’s 
instructions.  Counterstaining with Mayer’s hematoxylin aided in the morphologic 
evaluation of normal and apoptotic nuclei, in which normal nuclei were stained as 
blue and apoptotic nuclei as brown.  The number of TUNEL-positive cells was 
quantitated using Aperio scanning image analysis of sections.  DNase I treatment 
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was carried out as the positive control. 
 
Hydroxyproline Analysis 
    Heart ventricle tissue was ground with liquid nitrogen, and 10 mg tissue 
powder, 100 µL of distilled water and 100 µL of concentrated HCl (10 N) added 
to a glass vial with Teflon cap and hydrolyzed at 120°C for 24 h.  Hydrolyzed 
samples were transferred to a microcentrifuge tube and spun at 10,000 rpm for 3 
min to remove hydrolyzed residue from the sample, and supernatants used for 
the assay.  Briefly, according to manufacturer's instructions (#6017, Chondrex, 
Inc., Redmond, WA), samples were distributed to a 96-well plate, incubated with 
chloramine-T solution at room temperature for 20 minutes and incubated with 
dimethylaminobenzaldehyde (DMAB) solution for 30 minutes at 60°C.  
Absorbance was measured at 530 nm on a spectrophotometer (Molecular 
Devices, CA).  Hydroxyproline levels were calculated according to standards 
provided.  The results were expressed as total collagen (µg) /heart tissue (mg), 
assuming that collagen contains an average of 13.5% hydroxyproline. 
 
RNA extraction and real-time quantitative PCR (qRT-PCR) 
Total RNA was isolated from heart ventricles using Trizol Reagent (Sigma) 
according to the manufacturer’s instructions, except that DNase I treatment was 
incorporated.  RNA concentrations were determined using NanoPhotometer 
(Implen GmbH, München, DE).  Total RNA (2 μg) was converted into cDNA with 
SuperScript III First-Strand Synthesis System for RT-PCR (Invitrogen, USA) and 
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the mixture diluted without purification in sterile water and used for qRT-PCR 
analysis.  mRNA expression of specific genes was quantified using the 
LightCycler® 480 Real-Time PCR System (Roche Applied Science, Mannheim, 
Germany).  Forward and reverse primers used are as follows: brain natriuretic 
peptide (BNP) 5’-GTCAGTCGTTTGGGCTGTAAC-3’ (forward) and 5’-
AGACCCAGGCAGAGTCAGA-3’ (reverse); 18S rRNA 5’-
GCAATTATTCCCCATGAACG-3’ (forward) and 5’-
GGGACTTAATCAACGCAAGC-3’ (reverse).  These primers were ordered from 
Integrated DNA Technologies (Coralville, IA, USA); Universal probe library (UPL) 
probes #71 (BNP), #48 (18S rRNA) were obtained from Roche Applied Science.  
The qRT-PCR reactions were performed in duplicate in 15 μL reaction volume 
containing 2 μL 1:10 diluted cDNA and 1× LightCycler 480 Probes Master Mix.  
18S rRNA was selected as reference gene, for which cDNA samples were 
diluted 1:4000.  Data were evaluated by calibrator-normalized relative 
quantification with efficiency correction using the Light Cycler® 480 software 
version 1.5 (Roche Applied Science, Mannheim, DE).  The software calculated 
the relative amount of the target gene to the reference gene based on the 
crossing points.   
 
Statistical analysis 
All data are expressed as the mean ± SE for n = 5 to 12 mice per group, as 
detailed in the Figure Legends.  For body weight data, a linear mixed model was 
considered with fixed effects of treatment group, day and their interaction and 
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random effects of both the intercept and slope.  The slope of weight loss and the 
weight change at the end of the treatment were compared between two 
treatment groups based on the linear mixed model.  For data from other 
experiments, firstly a Bartlett’s test is used to test homogeneity of variance 
across all groups.  If the Bartlett’s test result was not significant, further statistical 
analysis was performed using a one-way ANOVA with post hoc analysis by the 
Newman-Keuls method.  If the Bartlett’s test result was significant, further 
statistical analysis was performed using Welch’s t-tests for pairwise comparisons 
between groups of interest with the Bonferroni correction for multiple comparison 
adjustment.  
 
Results 
Chronic DOX administration decreased mouse body weight and heart 
weight 
Mrp1-/- mice and their WT littermates were treated with either 3 mg/kg body 
weight, twice a week for 3 weeks (Figure 2.3 protocol A), or 2 mg/kg body weight, 
twice a week for 5 weeks (Figure 2.3 protocol B).  DOX markedly decreased 
body weight of WT and Mrp1-/- mice; after DOX treatment was discontinued and 
during the 2-week recovery period, body weight stabilized and began to recover 
in all DOX treated animals.  Comparison of the slope of weight loss for DOX-
treated Mrp1-/- vs WT mice and the weight change in the two groups at the end 
of the treatment (day 21 and 35 for the 3 and 2 mg/kg DOX treatment groups, 
respectively) showed that the magnitude of the decrease was significantly larger 
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in Mrp1-/- compared to WT mice (p < 0.001 for both comparisons).  With the 3 
mg/kg DOX treatment, 4 of 13 Mrp1-/- mice were euthanized due to severe body 
weight loss (22-25% of initial body weight) before the last day of the experimental 
period.  Thus, for subsequent experiments, except for the TUNEL assay, data 
were acquired using the lower DOX dose (2 mg/kg) treatment (Protocol B).  DOX 
treatment also significantly decreased heart weight in both genotypes (Figure 
2.4). 
 
Effects of chronic DOX administration on blood counts 
    Chronic DOX treatment (2 mg/kg) significantly decreased white blood cell 
(WBC) and lymphocyte (LY) counts in both genotypes 48 h after the last DOX 
treatment (Figure 2.5A and 2.5B).  Two weeks later, the WBC, including LY 
counts, had recovered in WT mice, but remained significantly decreased in  
Mrp1-/- mice (p < 0.05) (Figure 2.5C and 2.5D).   
 
Cardiac function after chronic DOX administration  
To determine whether cardiac contractile function was affected by chronic 
DOX administration, LVIDd and LVIDs were assessed by in vivo 
echocardiography 2 weeks after the last DOX treatment (2 mg/kg), and LVFS 
and LVEF calculated.  Figure 2.6A shows representative echocardiograms of WT 
and Mrp1-/- mice after saline or DOX administration.  There were no significant 
differences in LVFS and LVEF between WT and Mrp1-/- saline treated mice 
(Figure 2.6B), indicating that Mrp1-/- mice had normal basal contractile function.  
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DOX treatment increased both LVIDd and LVIDs and decrease LVPWd and 
LVPWs in WT and Mrp1-/- mice (Figure 2.6 B - E).  Importantly, DOX significantly 
reduced LVFS and LVEF in Mrp1-/- mice, while there were no significant 
changes in these values in WT mice (Figure 2.6F and 2.6G).   
B-type Natriuretic Peptide (BNP) is a cardiac hormone secrected from the 
ventricles of the heart in response to ventricular volume and pressure overload.  
Thus, elevated BNP expression was used as a heart failure marker.  Here, BNP 
mRNA expression was found to be significantly higher in DOX treated Mrp1-/- 
mouse heart compared to WT mouse heart (Figure 2.6H).  This was consistent 
with the cardiac dysfunction observed in DOX treated Mrp1-/- mice. These data 
clearly demonstrate that loss of Mrp1 exacerbated DOX-induced cardiac 
dysfunction. 
 
DOX-induced apoptosis in mouse heart 
The effects of Mrp1 on DOX-induced cell apoptosis in the heart was 
investigated using TUNEL staining to evaluate heart sections.  Cells containing 
intensive TdT-positive staining in the nuclei were considered apoptotic.  As a 
result, DOX treatment (3 mg/kg) increased apoptosis in mouse hearts of both 
genotypes, however, Mrp1-/- hearts showed significantly more extensive (~3.5 
fold higher) TUNEL staining nuclei compared to WT mice hearts (p < 0.05) 
(Figure 2.7), consistent with the more severe cardiotoxicity seen with 
measurements of ventricular systolic function. 
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Chronic DOX administration increased heart ventricular fibrosis 
Since DOX has been reported to induce cardiac fibrosis (Zhu et al., 2008; Li et 
al., 2006), the mouse ventricular fibrosis was examined by quantitating the 
collagen level.  As shown in Figure 2.8, saline treated WT and Mrp1-/- mice heart 
had similar collagen levels, while DOX treatment significantly increased 
ventricular collagen level in both WT and Mrp1-/- mice.  However, no significant 
difference in the collagen level was found between genotypes.  
 
Discussion  
The key finding in the present study is that global deletion of Mrp1 
potentiates DOX-induced cardiac toxicity in mice as measured by 
echocardiography, apoptosis and the ventricular dysfunction marker BNP.  DOX 
is an anti-tumor anthracycline that is effective in treating a wide variety of cancers, 
but produces dose-limiting cardiac toxicity.  Although all of the factors 
contributing to the mechanism for DOX-induced cardiotoxicity are not known, it is 
well accepted that oxidative stress contributes significantly to DOX-induced heart 
failure (Yen et al., 1996; Minotti et al., 2004; Kang et al., 2007).  Our group and 
others have shown that adduction of cardiac proteins with HNE, a toxic product 
of lipid peroxidation induced by oxidative stress, is increased in DOX treated 
mice (Renes et al., 2000; Jungsuwadee et al., 2006).  Additionally, sarcolemmal 
membrane vesicles from WT mouse heart transport GS-HNE, but this activity is 
absent in such vesicles from Mrp1-/- mice (Jungsuwadee et al., 2009).  In 
addition, 72 h after a single dose of DOX (15 mg/kg body weight, iv) there is 
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significantly more nuclear injury in Mrp1-/- compared to WT hearts (Deng et al., 
submitted).  Based on these findings, we hypothesized that Mrp1 protects 
against DOX-induced cardiac dysfunction.   
Here the previous findings were extended to assess whether loss of Mrp1 
affects cardiac function following DOX treatment.  The data show that chronic 
DOX treatment caused a more severe left ventricle dysfunction in Mrp1-/- mice, 
presenting as decreased LVFS and decreased LVEF.  These pathological 
changes were also consistent with the higher BNP expression and more 
apoptotic nuclei observed in Mrp1-/- mouse heart.  These data further 
demonstrated that loss of Mrp1 potentiated DOX-induced cardiac dysfunction in 
addition to the nuclear damage in heart, even though Mrp1-/- mice heart have 
higher GSH levels due to the loss GSH efflux via Mrp1 (Deng et al., submitted).  
Together, these data strongly support the hypothesis that Mrp1 protects the heart 
against DOX toxicity in vivo.  
Several ABC transport mRNA/proteins have been reported to be present to 
various degrees in heart (Couture et al., 2006), and could contribute to efflux of 
DOX.  Pgp (Abcb1a, Abcb1b), BCRP (Abcg2) and Mrp2 (Abcc2) were 
demonstrated to contribute to DOX resistance by mediating its efflux (Couture et 
al., 2006; Vlaming et al., 2006; Natarajan et al., 2012).  In addition, Mrp4 (Abcc4) 
is able to efflux GSH and GSSG (Ballatori et al., 2005).  It has been reported that 
there is no/very low expression level of Abcc2 in heart (Couture et al., 2006). 
Also we did not detect the protein expression of Abcg2 in heart tissue. To rule out 
potentially altered, compensatory expression of other transporters in the heart of 
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Mrp1-/- mice, we measured the protein expression of Abcb1 and Abcc4 2 weeks 
after the last dose of DOX or saline.  These data show that none of these 
transporters showed a significant difference between WT and Mrp1-/- mice heart 
following treatment with saline or DOX (Figure 2.9).   
Finally, decreased recovery from hematopoietic toxicity was seen in Mrp1-/- 
mice following DOX treatment.  This transient myelosuppression, shown as 
decreased WBC counts and LY counts in DOX treated mice, is probably caused 
by the suppression or apoptosis of hematopoietic progenitor cells.  But how Mrp1 
affects the replenishment of these blood cells is not clear.  Another key finding 
was that DOX treatment caused a more severe body weight loss in Mrp1-/- mice.  
This is likely associated with reduced food consumption, since DOX causes a 
loss of appetite in DOX-treated cancer patients.  It is also well-known that DOX 
causes dose-limiting gastrointestinal injury due to its toxic effect on intestinal 
epithelium, including the rapidly dividing stem cells located at the base of the 
intestinal crypts.  The apoptosis in intestinal epithelium and the loss of villi 
throughout the small intestine could compromise digestive and absorptive 
capacities, finally causing severe body weight loss in mice (Ijiri and Potten, 1987).  
However, since these Mrp1-/- mice are constitutive knockout animals, we could 
not determine whether the intestine or other organs were primarily responsible 
for this differential extent of body weight loss between WT and Mrp1-/- mice.  
In summary, loss of Mrp1 potentiates DOX-induced cardiotoxicity, showing a 
severe ventricular dysfunction and cellular apoptosis in heart tissue.  These 
studies are the first to document a protective role of Mrp1 in DOX-induced 
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cardiotoxicity and may provide critical information regarding the potential adverse 
sequelae of introduction of MRP1 inhibitors as adjuncts to clinical chemotherapy 
of multidrug resistant tumors.  
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Figure 2.1. Murine Mrp1 does not transport DOX due to critical amino acid 
differences with human MRP1.   The figure shows the predicted topology of 
human and murine MRP1/Mrp1 with 17 TM helices.  An expanded view of the 
region encompassing TM helix 14 is illustrated in the bottom half of the figure.  
The amino acids shown in the expanded view are those found in human MRP1.  
Residues in open circles are identical in the murine and human proteins.  
Residues that are different between the two proteins are indicated by shaded 
circles, and the amino acids present in murine Mrp1 at the equivalent positions 
are shown to the side.  L, leucine; M, methionione; K, lysine; E, glutamic acid; V, 
valine; F, phenylaline; G, glycine; I, isoleucine; D, aspartic acid; N, asparagin; S, 
Serine; P, proline; Q, glutamine; CL: cytoplasmic loops. 
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Figure 2.2. Chronic DOX treatment protocols.  Protocol A: WT and Mrp1-/- 
mice were administrated intraperitoneal DOX, 3 mg/kg body weight, or an 
equivalent volume of saline, twice a week for 3 weeks, resulting in a cumulative 
dose of 18 mg/kg DOX.  Protocol B: WT and Mrp1-/- mice were administrated 
intraperitoneal DOX, 2 mg/kg body weight, or an equivalent volume of saline, 
twice a week for 5 weeks, resulting in a cumulative dose of 20 mg/kg DOX. 
 
 
 
 
 
Total Cumulative Dose: 20 mg/kg 
Total Cumulative Dose: 18 mg/kg 
Protocol A 
Week 1 2 3 5 
Protocol B 
Week 1 2 3 5 4 7 
DOX 
(3 mg/kg, i.p.) 
2x 2x End 2x 
DOX 
(2 mg/kg, i.p.) 
2x 2x End 2x 2x 2x 
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Figure 2.3.  Body weight change during chronic DOX treatment.  WT and 
Mrp1-/- mice were administrated intraperitoneal DOX with protocol A (A) or 
protocol B (B), and maintained for an additional two weeks (“recovery”); animal 
weight was monitored throughout.  Arrow: one mouse was sacrificed on each of 
the indicated days due to body weight loss (loss of 22 - 25% of initial body 
weight). Values are mean ± SE.  (Panel A, n = 12; Panel B, n = 12 before day 35 
and n = 6 after day 35) 
A 
B 
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Figure 2.4. Heart weight change after chronic DOX treatment.   WT and 
Mrp1-/- mice were administered intraperitoneal DOX with protocols A (A) or B (B).  
Two weeks later, the hearts were removed immediately and weighed. Each bar 
represents the mean ± SE.  (In figure A, n= 12 for saline treated group; n=12 for 
DOX treated WT mice; n=10 for DOX treated Mrp1-/- mice; in figure B, n=6 for 
each group, *, p < 0.05 DOX vs. saline of the same genotype by Newman-Keuls 
multiple comparison test after one-way ANOVA) 
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Figure 2.5. The effects of DOX on white blood cell (WBC) and lymphocyte 
(LY) counts.   Mice were treated with protocol B, and WBC and LY counts 
measured 48 h (A and B) and 2 weeks (C and D) after the last DOX dose.  
Decreased WBC and LY counts were observed in both WT and Mrp1-/- mice at 
48 h after the last DOX dose, and had recovered two weeks later in WT mice, but 
remained depressed in Mrp1-/- mice.  K/µL, 1000 cells per microliter.  Each bar 
represents the mean + SE.  (n=8 for saline treated group; n=12 for DOX treated 
group, *, p < 0.05 DOX vs. saline of the same genotype; #, p < 0.05 Mrp1-/- vs. 
respective WT mice by Newman-Keuls multiple comparison test after one-way 
ANOVA). 
 
 
63 
 
 
 
 
                                       
                 
             
       
                                              
A 
B C 
D E 
F G 
64 
 
 
       
Figure 2.6. Chronic DOX treatment leads to more severe systolic 
dysfunction in Mrp1-/- mice vs. WT mice.  Mice were treated with protocol B, 
and cardiac function assessed through M-mode transthoracic echocardiography.  
(A) Representative M-mode echocardiogram of left ventricular (LV) wall motion;  
(B) LVIDd, (C) LVIDs, (D) LVPWd, (E) LVPWs, (F) Fractional shortening, (G) 
Ejection fraction and (H) mRNA expression of BNP analyzed by qRT-PCR 2 
weeks after chronic saline or DOX treatment.  Each bar represents mean ± SE. 
(n=8 for saline treated group; n=12 for DOX treated group; *, p < 0.05 DOX vs. 
saline of the same genotype; #, p < 0.05 Mrp1-/- vs. respective WT mice by 
Newman-Keuls multiple comparison test after one-way ANOVA). LVIDd: left 
ventricular end-diastolic dimension; LVIDs: left ventricular end-systolic dimension; 
LVPWd, left ventricular diastolic posterior wall thickness; LVPWs, left ventricular 
systolic posterior wall thickness. 
  
H 
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Figure 2.7. Apoptosis in mouse myocardium.  Mice were treated using 
protocol A, and apoptosis from mouse myocardium detected by TUNEL 
(Terminal deoxynucleotidyl transferase dUTP nick end labeling assay) staining.  
Representative photomicrographs are shown demonstrating TUNEL staining of 
heart sections from saline treated WT (A), DOX treated WT (B), saline treated 
Mrp1-/- (C), and DOX treated Mrp1-/- mice (D).  TUNEL-positive cells are 
indicated by brown staining, and the TUNEL-positive nuclei are indicated by 
E 
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arrows.  (E) Histogram showing the quantitative analysis of TUNEL-positive cells.  
Each bar represents mean ± SE (n=6 for saline treated group; n= 10 for DOX 
treated WT mice, n=8 for DOX treated Mrp1-/- mice.  *, p < 0.05 DOX vs. saline 
of the same genotype; #, p < 0.05 Mrp1-/- vs. respective WT mice by Welch’s t-
test.) 
 
 
                 
                         
Figure 2.8. DOX increased collagen level in mouse heart.  Mice were treated 
using protocol B, and hydroxyproline levels in mouse heart tissue measured.  
The results are expressed as total collagen/heart tissue, assuming that collagen 
contains an average of 13.5% hydroxyproline.  Each bar represents the mean ± 
SE.  (n = 8, *, p < 0.05 DOX vs. saline of the same genotype by Newman-Keuls 
multiple comparison test after one-way ANOVA).   
 
 
 
 
* 
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Figure 2.9. Protein expressions of Abcb1 and Abcc4 in mouse heart. Mice 
were treated with protocol B, and the protein level of Abcb1 and Abcc2 were 
measured 2 weeks after the last dose of DOX by real time PCR.  Each bar 
represents the mean ± SE. (n = 3) 
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Chapter Three 
 
Mrp1 protects both cardiomyocytes and cardiac fibroblasts against DOX 
cytotoxicity 
 
Overview of Study 
    The studies in chapter 2 demonstrated that loss of Mrp1 potentiates chronic 
DOX treatment induced cardiotoxicity in mice, presenting more severe left 
ventricle dysfunction and greater cell apoptosis in Mrp1-/- mouse heart.  Here, to 
extend the findings of Mrp1’s cardiac protective role to a cellular level, and 
identify the specific function of Mrp1 in different cell types in heart, the effects of 
Mrp1 on DOX cytotoxicity in cardiomyocytes (CM) and cardiac fibroblasts (CF) 
was further investigated.  Neonatal mouse CM and CF, isolated from WT and 
Mrp1-/- 1-3 days old pups, were treated with DOX (0.3 - 4 μM) for various times.  
DOX significantly increased Mrp1 mRNA and protein expression level in both CM 
and CF cultures.  The methyl thiazol tetrazolium (MTT) assay showed that CM 
and CF derived from Mrp1-/- mice demonstrate a greater decrease in cell viability 
after DOX treatment.  Further studies suggested that there was more cell 
apoptosis and DNA damage in DOX treated Mrp1-/- cells, presenting as higher 
caspase 3 cleavage, PARP cleavage and γH2.AX expression vs WT cells.  
Taken together, these results indicate that Mrp1 protects both CM and CF 
against DOX induced cytotoxicity. 
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Introduction  
    Cardiotoxicity is one of the most serious side effects in DOX treated cancer 
patients.  Identifying the gene(s) involved in normal hearts’ defense against this 
toxicity and understanding the mechanisms will be very helpful to find the 
potential approaches to prevent or alleviate this dose-limiting toxicity.  Our in vivo 
studies demonstrate that loss of Mrp1 potentiates chronic DOX treatment 
induced cardiotoxicity in mice, with Mrp1-/- mice exhibiting more nuclear injury 
after a single DOX injection and more severe cardiac dysfunction and greater 
heart apoptosis following chronic DOX treatment.    Here, to extend the bases of 
Mrp1’s cardiac protective role to a cellular level, the role of Mrp1 in DOX toxicity 
in cardiomyocytes (CM) and cardiac fibroblasts (CF) was further evestigated. 
CM and CF form the two largest cell populations in heart, while other cell types, 
such as endothelial or vascular smooth muscle cells, represent comparatively 
small populations.  CMs are the major cells that make up the atria and ventricles 
of the heart, and account for more than 50% of total cell number in heart.    
During fetal life, cardiomyocyte DNA synthesis is associated with cell proliferation, 
and after birth (up to approximately neonatal day 3) a second DNA synthesis 
phase is associated with binucleation.  After that, cardiac growth involves 
increasing the size of the myocytes without substantial increases in cell number 
(Woodcock et al., 2005).  The low proliferative capacity of adult CMs means that 
loss of working CMs in adult heart cannot be replaced and must be compensated 
by increased work load of the remaining myocytes; otherwise, cardiac 
dysfunction will develop.  This also partially explains why the heart is so 
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susceptible to DOX toxicity compared to other tissues with better self-
regeneration capacity.  The CMs are able to shorten through the interaction 
between myofilament proteins actin and myosin, and these cells must be able to 
shorten and lengthen properly to maintain normal cardiac structure and function.  
A rapidly expanding body of evidence indicates that CM death by apoptosis and 
necrosis is an important mechanism of DOX-induced cardiomyopathy (Zhang et 
al., 2009; Octavia et al., 2012). 
    CFs are the most abundant non-cardiomyocytes within the heart.  They are 
found throughout cardiac tissue surrounding CM and bridging ‘the voids’ between 
myocardial tissue layers.  Compared to CM, the understanding of CF function is 
much less.  CFs provide a supporting structure to the healthy heart, contribute to 
myocardial structure, cell signaling, and electro-mechanical function in healthy 
myocardium (Camelliti et al., 2005).  Beyond their very important roles in 
maintaining myocardial function under normal condition, CFs also contribute to 
adverse cardiac remodeling during pathological conditions, such as hypertension, 
myocardial infarction, and heart failure (Souders et al., 2009; Shi et al., 2011).  
Upon cardiac injury, CFs may proliferate and secret extracellular matrix and 
growth factor, leading to scar formation, cardiac fibrosis, myocardial stiffening 
and finally, cause cardiac dysfunction.  Emerging research indicates that CFs are 
involved in arrhythmia initiation and maintenance by affecting electrical 
propagation (Kamkin et al., 2005). 
    The previous study in our laboratory and the data in Chapter 2 showed the 
cardiac protective function of Mrp1 in DOX treated mice (Deng et al., submitted).  
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Here, to further extend our findings to a cellular level, the effects of Mrp1 on DOX 
cytotoxicity was further investigated in the two major cell populations in heart: CM 
and CF.  The results showed that in neonatal CM and CF cultures, DOX 
increased Mrp1 expression at both mRNA level and protein levels.  CM and CF 
derived from Mrp1-/- mice were more sensitive to DOX toxicity, presenting lower 
cell survival, more cell apoptosis and more DNA damage.  These data 
demonstrated that Mrp1 protects both CM and CF against DOX toxicity. 
 
Materials and methods 
Neonatal mouse CM/CF isolation and culture  
    C57BL/6 (WT) mice and Mrp1-disrupted C57BL/6 (Mrp1-/-) mice were 
backcrossed for more than ten generations.  Experiments complied with the 
requirements of the Institutional Animal Care and Use Committee of the 
University of Kentucky (Lexington, KY).    Primary CM and CF were obtained 
from Mrp1-/- neonatal mice and their WT littermates at 1–3 days of age.  Mice 
were sacrificed by cervical dislocation, hearts were removed aseptically with the 
ventricles only retained and maintained in cold Hanks’ balanced salt solution 
(HBSS) without Ca2+ and Mg2+.  The ventricles were washed with the same 
HBSS and minced into small fragments that were subjected to enzymatic 
digestion in the HBSS with collagenase type 2 (Worthington Biochemical Corp., 
Lakewood, NJ).  Serial cycles of agitation were performed.  After each cycle, the 
supernatant (containing the isolated cells) was removed and FBS added to a final 
concentration of 10%, the resulting mixture centrifuged for 10 min at 100 g, and 
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then the cells resuspended in DMEM with 10% FBS (v/v), 100 units/ml penicillin, 
and 100 μg/ml streptomycin (GIBCO, Grand Island, NY).  Cells were preplated 
for 2 h at 37°C, to obtain CM and non-myocyte cells, predominantly CF.  For CM 
culture, 100 μmol/L Bromodeoxyuridine (Sigma Chemical Co.) was added during 
the first 48 h to prevent proliferation of nonmyocytes.  CM purity was tested by 
staining with antibody to cardiac-sarcomeric actin according to the 
manufacturer’s instructions (Sigma Chemical Co).  CM purity averaged >95% 
when examined after 48 h of culture.  CF cultures were examined for positivity of 
expression of vimentin by immunofluorescence (Figure 3.1).  Mouse anti-
vimentin mAb (sc73259) was purchased from Santa Cruz Biotechnology (Santa 
Cruz, CA).  CF cultures were used for experiments after two passages to 
eliminate other nonmyocytes  
 
Methyl thiazol tetrazolium (MTT) assay 
The cytotoxicity of DOX was determined by the MTT test.  WT and Mrp1-/- CM or 
CF cells were seeded and grown in a 96-well plate at 37°C in a 5% 
CO2 saturated atmosphere overnight.  To develop a dose-response curve, DOX 
stock solution (2 mg/ml, Pfizer, NY) was dissolved in culture medium to final 
concentrations of 0 - 4 µM, and was incubated with cells in culture for 3 h, after 
which the media containing DOX was removed.  Cells were rinsed once with 1× 
PBS, and finally incubated with fresh media for an additional 48 h.  The MTT 
assay was performed according to the manufacturer’s instructions (CellTiter 96 
Aqueous One Solution Cell Proliferation Assay, Promega, Madison, WI).  The 
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absorbance at 480 nm was measured for each well by SpectraMax M5 multi-
detection reader (Molecular Devices, CA).  The absorbance of untreated control 
cells was taken as 100% viability and the values of treated cells were calculated 
as a percentage of control.  The data are represented as mean ± SE from 3 
independent experiments.     
 
Measurement of DOX concentration in cells 
     WT and Mrp1-/- CM or CF cells (106) were seeded and grown in a 12-well 
plate at 37°C in a 5% CO2 saturated atmosphere overnight.  Cells were treated 
with 30 µM DOX.  Following 1 h of incubation, cells were washed three times with 
PBS and incubated with fresh DMEM medium for the indicated time.  Finally, the 
cells were washed three times with PBS and incubated in 75% acidified (0.75 N 
HCl) isopropanol with 1% Triton X-100 and shaken for 30 min at room 
temperature.  The absorbance of the supernatant was read using a fluorescence 
spectrofluorometer at wavelengths of Ex=470 nm and Em=590 nm.  The value of 
DOX accumulation within the cells was calculated according to the standard 
curve.    
 
RNA extraction and real-time quantitative PCR (qRT-PCR) 
Total RNA extraction, cDNA preparation and qRT-PCR were conducted as the 
method description in Chapter 2.  PCR primers for Mrp1 are as follows: Mrp1 5’-
tgtgggaaaacacatctttga-3’ (forward) and 5’-ctgtgcgtgaccaagatcc-3’ (reverse); 18S 
rRNA 5’-gcaattattccccatgaacg-3’ (forward) and 5’-gggacttaatcaacgcaagc-3’ 
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(reverse).  Universal ProbeLibrary probes #105 (Mrp1), (18S rRNA) were 
obtained from Roche Applied Science. 
 
Immunoblot Assay 
    Protein concentrations were determined with the bicinchoninic acid protein 
assay (Pierce, Rockford, IL).  Protein samples were fractionated on a 4% to 12% 
SDS-PAGE gel (EC6038BOX, Life Technologies) and transferred to 
nitrocellulose (Whatman, Stanford, ME).  The blots were incubated with the 
primary antibody diluted in TBS/5% nonfat milk/0.1% Tween 20 at 4⁰C overnight, 
then washed in TBS/0.1% Tween 20, and subsequently incubated with 
horseradish peroxidase (HRP)-labeled secondary antibody in TBS/5% nonfat 
milk/0.1% Tween 20. Chemiluminescence detection was done using Enhanced 
Chemiluminescence Plus (RPN2236, GE Healthcare, UK).  Antibodies were 
obtained as follows: rat anti-Mrp1 mAb (801-007-c250; Alexis, San Diego, CA), 
rabbit anti-GAPDH pAb (sc-25778) and rabbit anti-actin pAb (sc-1616-R Santa 
Cruz Biotechnology, Santa Cruz, CA), rabbit anti-PARP pAb (#9542), rabbit anti-
cleaved caspase3 pAb (#9661) and rabbit anti–phospho-histone H2A.X (γH2A.X) 
pAb (Ser139) (#9718) from Cell Signaling (Beverly, MA, USA), anti-rat Ig-HRP, 
anti-rabbit Ig-HRP and anti-mouse Ig-HRP from Amersham Biosciences 
(Piscataway, NJ).    
 
Statistical analysis 
    All data are expressed as the mean ± SD for n = 3 to 6 per group, as detailed 
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in the Figure Legends.  In studies comparing two groups, statistical analysis was 
performed with the Student’s t-test.  In studies comparing multiple groups to the 
same control group, statistical analysis was performed with one-way ANOVA 
followed by Dunnett's post-test.  In studies comparing more than two groups, 
statistical analysis was performed with one-way ANOVA followed by Newman-
Keuls multiple comparison test. 
 
Results 
DOX upregulates Mrp1 expression in CM and CF 
To examine the effect of DOX on expression of Mrp1, CM and CF were 
isolated from WT neonatal mouse heart tissue and treated with DOX for 24 h, 
then expression of Mrp1 analyzed by Real-time PCR and Western blotting.  As 
shown in Figure 3.2, Mrp1 was constitutively present in CM and CF.  Moreover, 
DOX treatment significantly increased both Mrp1 mRNA (Figure 3.2A) and 
protein expression (Figure 3.2C) in CM in a concentration-dependent manner.  A 
similar pattern was also observed in CF cultures (Figure 3.2B and Figure 3.2D).  
GAPDH was used as a protein loading control, as the expression of GAPDH did 
not change with DOX treatment.  These results showed that DOX enhanced 
Mrp1 expression in cultured neonatal mouse CM and CF, implying that this 
protein could be involved in the cellular response to DOX.    
 
Effect of Mrp1 on DOX-induced caytotoxicity 
    To characterize the role of Mrp1 in DOX resistance in a cell type specific 
manner, cytotoxicity of DOX in WT and Mrp1-/- CM and CF was measured by 
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MTT assay.  As shown in Figure 3.3A, after 3 h of DOX treatment following 
incubation with DOX-free media for another 48 h, 0.3, 1 and 3 µM DOX 
decreased viability, shown as mean ± SD, to 64±3%, 35±3% and 11±2%, 
respectively, in Mrp1-/- CM, compared to 75±2%, 52±6% and 25±5% viability in 
WT (p < 0.05). Similar experiments in CF cultures demonstrated again that CF 
isolated from Mrp1-/- mice showed enhanced DOX toxicity (Figure 3.3B).  The 
expression of Mrp1 was only detected in WT cells but not Mrp1-/ cells.  These 
results indicated that Mrp1 protects both CM and CF against DOX cytotoxicity.    
 
Effect of Mrp1 on DOX-induced cell apoptosis and DNA damage     
    In order to understand the mechanism of cell death, apoptosis-related proteins 
were chracterized in WT and Mrp1-/- CM and CF.  DOX treatment increased 
PARP cleavage, caspase3 cleavage, and these increases were significantly 
greater in Mrp1-/- CM compared to WT CM (Figure 3.4A).  Similar results were 
observed in CF cultures (Figure 3.4B).     
    The DNA damage was further assessed by quantitating expression of γH2AX. 
The increased expression of γH2AX was observed at early time points and 
continuously increased over time (0, 3, 6 and 9 h after treatment with DOX) 
(Figure 3.5A).  Consistent with the results obtained by measure of PARP 
cleavage and caspase 3 cleavage, γH2AX expression was statistically 
significantly higher in Mrp1-/- CM compared to WT CM at 24 h after DOX 
treatment (Figure 3.5B). Similar results were observed in CF cultures (Figure 
3.5C and D).  These results indicated greater apoptosis and DNA damage in 
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Mrp1-/- CM and CF following DOX treatment compared with WT cells.     
    Although no evidence has shown that murine Mrp1 is able to transport DOX, 
and in our previous study in mouse model, there is no significant difference of 
DOX concentration between WT and Mrp1-/- mouse heart tissue at 3, 6 12 h 
after a single intravenous administration of 15 mg/kg DOX (Deng et al, 
submitted), the intracellular DOX accumulation in WT and Mrp1-/- cells was 
further examined.  As shown in Figure 3.6, there is no significant difference in 
DOX intracellular retention between genotypes.  These data ruled out the 
possibility of different intracellular DOX accumulation as the cause of the different 
susceptibility to DOX in WT and Mrp1-/- cells.  Because fluorescence was used 
as the method of detection, fluorescent DOX metabolites may be contributing to 
the total DOX concentration. 
 
Discussion  
DOX is effective in treating a wide variety of cancers, but produces dose-
dependent cardiac toxicity.  Our group has shown that loss of Mrp1 in C57BL 
mice potentiates acute DOX treatment induced heart nuclear injuries and chronic 
DOX treatment-induced cardiac toxicity, including impaired left ventricular 
systolic function and increased heart apoptosis (Deng et al., submitted; Chapter 
2). The key finding in the present study is that deletion of Mrp1 potentiates DOX-
induced toxicity in both CM and CF in a dose-dependent manner.     
It is well known that the heart is comprised of a syncytium of CM and 
surrounding nonmyocytes, the majority of which are CF.  These two types of cells 
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are highly interspersed in the myocardium and more and more evidence shows 
that bidirectional cross talk between CM and CF plays important roles in 
determining cardiac mechanical and electrical function in both normal and 
diseased hearts.  Therefore, this current study investigated how Mrp1 affects 
DOX toxicity in these two different cells types. 
    Mrp1 was consistently expressed in cultured neonatal mice CM and CF, and 
DOX treatment increased Mrp1 expression in a dose-dependent manner.  More 
importantly, Mrp1-/- cells were more sensitive to DOX-induced cytotoxicity, 
showing a lower cell survival, higher caspase 3 cleavage, PARP cleavage and 
higher γH2AX expression.  These data clearly demonstrated that Mrp1 protects 
both CM and CF against DOX toxicity, and also agreed with the results in 
Chapter 2 showing a cardiac protective function of Mrp1 in the chronic DOX-
treated mouse model.  However, beyond the apoptosis and DNA damage, it is 
possible that other mechanisms are involved in the protective effects provided by 
Mrp1, based on the physiologic function of CM and CF.  For example, a large 
body of evidence shows that beyond the maintenance of normal structure and 
function of the heart (Souders et al., 2009), CF serve as a source of mitogens, 
extracellular matrix proteins, growth factors, and cytokines that could affect the 
phenotype of CM.  In addition, crosstalk between CF and CM is important for 
both cardiac development and remodeling in response to injury (Ottaviano et al., 
2011).  How Mrp1 could attribute to this communication between CM and CF 
needs to be further studied.    
    Transcriptional regulation of Mrp1 upon treatment with DOX has been shown 
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to involve many transcription factors, including Sp1, antioxidant response 
element (ARE), and the JNK pathway.   Oxidative stress induces nuclear factor-
like 2 (Nrf2) translocation from the cytosol to the nucleus and binding with ARE, 
and finally induce the transcription of Mrp1 and antioxidative genes (Hayashi et 
al., 2003; Itoh et al., 2003; Nguyen et al., 2005).  Our laboratory have shown that 
upon DOX treatment of mice, Mrp1 expression in sarcolemma increases within 6 
h and remains elevated for 24 h (Jungsuwadee et al., 2006).  In this study, DOX 
treatment significantly induced Mrp1 mRNA and protein expression in both CM 
and CF in a dose-dependent manner.   Induction of Nqo1 and HO-1, two typical 
downstream genes of the Nrf2 pathway, was also observed in CM and CF after 
DOX treatment (data shown in Chapter 4).  These data imply that in CM and CF, 
Mrp1 expression is increased by the activation of the Nrf2 pathway under DOX-
induced oxidative stress. 
    In summary, the key finding of this in vitro study is that loss of Mrp1 
potentiates DOX cytotoxicity in CM and CF culture, presenting as more severe 
apoptosis and DNA damage.  It confirms the cardiac protective function of Mrp1 
in vivo as shown in Chapter 2.  Taken together, these data provide strong 
evidence indicating that Mrp1 provides protection in CM and CF in the face of 
DOX cytotoxicity.   
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Figure 3.1. Identification of neonatal mouse cardiomyocytes (CM) and 
neonatal mouse cardiac fibroblasts (CF).  (A) Representative 
immunofluorescent staining for α-actinin (red fluorescence) in CM (A, left). A, 
right: negative control (use of mouse IgG instead of α-actinin antibody) in CF 
culture.  (B) Representative immunofluorescent staining for anti-vimentin (red 
fluorescence) in CF (B, left). B, right:   negative control (use mouse IgG instead 
of anti-vimentin antibody) in CF culture. DAPI (4',6-diamidino-2-phenylindole) 
staining was used to identify individual nuclei.   
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Figure 3.2. DOX increased Mrp1 expression in CM and CF culture.  
Quantitative analysis of Mrp1 mRNA expression (detected by Real - Time PCR) 
in CM (A) and CF (B) 24 h after treatment with saline or varying concentrations of 
DOX.  Quantitative analysis of Mrp1 protein expression (detected by Western 
blot) in CM (C) and CF (D) 24 h after treatment with saline or DOX.  The blots are 
representative of one of 3 independent experiments.  Each bar represents the 
mean + SD.   (*, p < 0.05 by Dunnett's post-test after one-way ANOVA) 
C 
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Figure 3.3. Effects of DOX on cell viability in WT and Mrp1-/- cells.  CM (A) 
and CF (B) were cultured on a 96-well plate for 48 h before treatment with 
varying concentrations of DOX for 3 h, followed by incubation in fresh medium.  
Tetrazolium reduction was measured 48 h after DOX removal.  Each point 
represents the mean ± SD from 3 independent experiments.   Expression of 
Mrp1 was detected by Western blot in WT and Mrp1-/- CM (A) and CF (B) (*, p < 
0.05 by Student’s t-test)  
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Figure 3.4. Effects of DOX on cell apoptosis in WT and Mrp1-/- cells.   The 
greater increase of cleaved PARP, and cleaved caspase-3 in CM (A) and CF (B) 
derived from Mrp1-/- mice was detected by Western blot 24 h after DOX removal.  
The blots are representative of one of 3 independent experiments.   Each bar 
represents the mean ± SD.   (*, p < 0.05 by Newman-Keuls multiple comparison 
test after one-way ANOVA) 
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Figure 3.5 A and B. Effects of DOX on DNA damage in WT and Mrp1-/- CM.   
The greater increase of γH2A.X in CM derived from Mrp1-/- mice was detected 
by Western blot 0 h, 3 h, 6 h, 12 h (A) and 24 h (B) after DOX removal.  The blots 
are representative of one of 3 independent experiments.  Each bar represents 
the mean ± SD. (*, p < 0.05 by Newman-Keuls multiple comparison test after 
one-way ANOVA).     
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Figure 3.5 C and D. Effects of DOX on DNA damage in WT and Mrp1-/- CF.   
The greater increase of γH2A.X in CF derived from Mrp1-/- mice was detected by 
Western blot 0 h, 3 h, 6 h, 12 h (C) and 24 h (D) after DOX removal.  The blots 
are representative of one of 3 independent experiments.  Each bar represents 
the mean ± SD.  (*, p < 0.05 by Newman-Keuls multiple comparison test after 
one-way ANOVA).     
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Figure 3.6.  Accumulation of DOX in WT and Mrp1-/- CM and CF.   Cells were 
treated with 30 µM DOX.  Following 1 h of incubation, cells were washed three 
times with PBS and incubated with fresh DMEM medium for the indicated times.   
Finally, the cells were washed three times with PBS and incubated in acidified 
(0.75 N HCl) isopropanol with 1% Triton X-100 and shaken for 30 min at room 
temperature. The absorbance of the supernatant was read using a fluorescence 
spectrofluorometer at wavelengths of Ex=470 nm and Em=590 nm.  The value of 
DOX accumulation within the cells was calculated according to the standard 
curve.   Each point represents the mean ± SD (n = 3). 
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Chapter Four 
 
Mechanisms of Mrp1’s cardiac protective function 
 
Overview of Study  
    The data presented in Chapter 2 demonstrated that the loss of Mrp1 
potentiates DOX-induced cardiac dysfunction in mice.  Chapter 3 further revealed 
the protective role of Mrp1 against DOX toxicity in two major cell components of 
heart tissue: cardiomyocytes and cardiac fibroblasts.  This chapter explores the 
mechanisms involved in Mrp1’s protection against DOX toxicity. 
    In the present study, GSH and GSSG levels were measured to evaluate the 
redox status in chronic DOX-treated mouse heart and CM/CF culture.  
Expression of GSH synthesis enzymes was measured to examine the possible 
mechanisms responsible for the changes in GSH levels.  The GS-HNE levels in 
mouse heart were also assessed by LC/MS/MS.  The protein oxidative damage 
in CM and CF culture were also measured, including protein carbonyl, HNE-
protein adducts and 3 nitrotyrosine-protein adducts.  Multiple antioxidant 
enzymes expression levels were also examined.  The results showed that loss of 
Mrp1 caused increased GSH and GSSG levels in untreated or saline treated 
mouse heart and in CM/CF culture.  Following 0.5 μM DOX treatment, Mrp1-/- 
CM showed increased GSH (1.7±0.3-fold) and GSSG (1.8±0.2-fold) levels 
relative to WT CM (p < 0.05), however the redox potential (Eh) of the GSH/GSSG 
pool was not changed.  Similar effects were observed in CF.  The increased GSH 
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pool after DOX treatment in Mrp1-/- cells is at least partially due to the increased 
GSH synthesis since DOX increased mRNA and protein expression of the rate-
limiting GSH synthesis enzymes glutamate-cysteine ligase catalytic (GCLc) and 
glutamate-cysteine ligase regulatory subunits (GCLm) in Mrp1-/- but not WT cells.  
DOX treatment increased GS-HNE levels in mouse heart, but without an obvious 
difference between genotypes. Finally, expression of extracellular superoxide 
dismutase (ECSOD/SOD3) was lower in Mrp1-/- CM vs. WT CM treated with 
either saline (62±8% of WT) or DOX (43±12% of WT) (p < 0.05).  Taken together, 
these data clearly showed that Mrp1 affected the intracellular GSH and GSSG 
levels in mouse heart tissue as well as in the CM and CF culture.  In treatment-
naïve Mrp1-/- mouse heart and cells, the higher GSH level is likely due to the 
loss of efflux mediated by Mrp1.  But with DOX treatment, the further increase of 
the GSH pool in Mrp1-/- CM and CF involves the activation of the Nfr2 pathway 
and increased GSH synthesis.  Unlike our hypothesis, loss of Mrp1 does not 
affect the intracellular level of GS-HNE in DOX treated mouse heart, implying 
that complex compensatory effects occur.  
 
Introduction 
GSH is the most abundant cellular non-protein thiol and is a critical factor 
responsible for the maintenance of cellular redox balance under oxidative stress.  
In the presence of ROS, GSH is rapidly oxidized to GSSG, resulting in a 
decreased intracellular GSH/GSSG ratio, an indicator of oxidative stress.  
Maintenance of GSH homeostasis plays a vital role in a multitude of cellular 
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processes, including drug and free radical detoxification, cell differentiation, 
proliferation and apoptosis (Jones, 2008).  Mrp1-/- mice have increased basal 
levels of GSH due to the decreased Mrp1-mediated efflux, while overexpression 
of Mrp1 decreases intracellular levels of GSH (Cole et al., 1990; Rappa et al., 
1997).  Our previous study showed that the treatment-naïve Mrp1-/- mouse heart 
has a significantly higher GSH level compared to WT mice.  In addition, Mrp1 
also mediates the efflux of GSSG so that loss of Mrp1 could potentially disrupt 
the balance of the GSH/GSSG redox couple, impairing a normal tissue’s ability to 
protect itself against oxidative stress-induced injury. 
    HNE is an α, β-unsaturated aldehyde derived from peroxidation of ω-6 
polyunsaturated fatty acids, and a toxic product of lipid peroxidation (Esterbauer 
et al. 1991; Butterfield and Stadtman 1997).   It is partially detoxified by 
conjugation with GSH, either spontaneously or through GSH-S-transferase (GST) 
to form GS-HNE, which must be effluxed to alleviate intracellular toxicity (Volkel 
et al., 2005).  Our laboratory had previously reported that mutant MRP1 
Gly671Val impairs MRP1’s ability to efflux GS-HNE by more than 80% 
(Jungsuwadee et al., 2012).  Also, the HEK cells that overexpress this mutant 
MRP1 (Gly671Val) are more sensitive to DOX toxicity relative to cells expressing 
wild-type MRP1.  Furthermore, HNE adducted protein is increased in mouse 
heart after DOX treatment and sarcolemmal membrane vesicles from Mrp1-/- 
mouse are unable to transport GS-HNE, indicating that Mrp1 is the only ATP 
dependent efflux transporter present in the mouse heart (Jungsuwadee et al., 
2006).   
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    Aerobic organisms possess antioxidant defense systems to protect cells 
from the damage caused by ROS.  Superoxide dismutase (SOD) and catalase 
are two important antioxidant enzymes which remove •O2
- and H2O2, respectively 
and maintain the normal redox status in cells.  Thus, the regulations of these 
genes at both expression and activity levels play pivotal roles in balancing the 
concentration of ROS.   SOD converts two •O2
- into one molecule of H2O2 and 
one molecule of O2, while catalase further catalyzes the decomposition of H2O2 
into H2O and O2.  In mammals, three distinct isoforms of SOD have been 
identified and characterized: copper-zinc superoxide dismutase 
(Cu,ZnSOD/SOD1), manganese superoxide dismutase (MnSOD/SOD2) and 
extracellular superoxide dismutase (ECSOD/SOD3).  Three forms of SOD 
convert •O2
- into H2O2, but have distinct protein structures, metal cofactor 
requirements, and intracellular localizations (Miao and St Clair, 2009).  
Cu,ZnSOD is localized mainly in cytoplasm and nucleus, while MnSOD resides in 
the mitochondrial matrix.  The physiological role of MnSOD has been 
demonstrated in that MnSOD knockout mice died shortly after birth with dilated 
cardiomyopathy and neurodegeneration (Li et al., 1995; Lebovitz et al., 1996).  
Further, overexpression of MnSOD in mice protects heart against DOX-induced 
cardiotoxicity (Yen at el., 1996; Yen at el., 1999).  ECSOD is a copper- and zinc-
containing dismutase and it is the only isoform of SOD responsible for 
scavenging •O2
- in the extracellular environment.  It is a glycosylated 
homotetrameric enzyme (155 kDa) that is secreted from cells to bind heparin 
sulfate proteoglycans on the cell surface and in the extracellular matrix.  There, 
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ECSOD converts •O2
- into less toxic H2O2.  In addition, ECSOD plays a key role 
in preserving the bioavailability of nitric oxide by protecting it against destruction 
by •O2
- and formation of highly toxic peroxynitrite.  Despite their effects on 
maintaining the normal redox status, antioxidant enzymes are also regulated by 
oxidative stress at both the expression level and activity level (Li and Singal, 
2000; Franco et al., 1999).  
GSH, GSSG and GS-HNE are substrates of Mrp1, and they are either 
related to redox status regulation or are toxic oxidative stress products 
themselves.  Thus, we expected that Mrp1 plays an important role in oxidative 
stress regulation.  In this chapter, experiments were conducted to explore how 
Mrp1 affects GSH, GSSG, and GS-HNE intracellular levels as well as expression 
of other antioxidant enzymes. 
 
Materials and methods 
Measurement of GS-HNE in mouse heart by LC-MS/MS 
Heart ventricle (50 mg tissue), prepared by removal of the atrium and 
attached fat tissue and vessels, was homogenized in 400 μL of distilled water 
followed by addition of 50 μL of 1 μM d3-GS-HNE.  The chemical purity of d3-GS-
HNE was determined by LC-MS.  Proteins were precipitated from heart 
homogenate by adding 1600 μL of ice-cold acetonitrile followed by vortexing for 5 
min and centrifugation at 4000 rpm for 10 min.  The supernatant was transferred 
to a 4 mL glass vial and dried under N2.  The dried samples were reconstituted in 
100 μL of acetonitrile:H2O (50:50), vortexed and let stand at room temperature 
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for 10 min, and centrifuged at 15000 rpm for 5 min.  The supernatants were then 
transferred to autosampler vials.  Analysis of GS-HNE was carried out using a 
Shimadzu High performance Liquid Chromatograph coupled with an AB Sciex 
4000-Qtrap hybrid linear ion trap triple quadrupole mass spectrometer (MS) 
operated in multiple reaction monitoring (MRM) mode.  The samples were 
separated on a Machery-Nagel Nucleodur C8 Gravity column (2.0 mm×125 mm, 
5 µm) by gradient elution with 0.05% formic acid in water (solvent A) and 
acetonitrile: water (95:5) containing 0.05% formic acid (solvent B) according to 
the following program: 100% solvent A for the first 1 min, then linear to 100% 
solvent B over the next 3 min, and maintained at 100% B for the last 2 min.  The 
column was equilibrated back to the initial conditions within 3 min.  The flow rate 
was 0.5 mL/min with a column temperature of 30°C.  The sample injection 
volume was 10 µL.  The MS was operated in the positive electrospray ionization 
mode with optimal ion source settings with a declustering potential of 71 V, 
entrance potential of 10 V, collision energy of 21 V, collision cell exit potential of 
8 V, curtain gas of 20 psi, ion spray voltage of 5500 V, ion source gas1/gas2 of 
40 psi and temperature of 550°C.  MRM transitions monitored were as follows: 
464.2/308 and 464.2/446.  d3-GS-HNE was used as an internal standard for 
quantitation of GS-HNE with the following MRM ion transitions: 467.2/308.1 and 
467.2/449.  Both pairs of fragments gave very similar quantitative results and 
data presented in this dissertation are based on the fragments 464.2/446. 
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Heart ventricle homogenate  
The heart ventricle was prepared by removal of the atrium and attached fat 
tissue and vessels, and then homogenized in 10 volumes of ice-cold buffer 
consisting of 0.225 M mannitol, 0.075 M sucrose, 1 mM EGTA, and protease 
inhibitors (1 mM phenylmethyl sulfonyl fluoride, 1 μg/mL leupeptin, 1μg/mL 
aprotinin, and 1 μg/mL pepstatin).  The protein concentrations of heart ventricle 
homogenates were determined with the bicinchoninic acid (BCA) protein assay. 
 
HPLC assay of GSH and GSSG 
For animal study, heart ventricle homogenate prepared as above was used 
for GSH derivatization and quantification of GSH and GSSG.  For cell culture 
study, CM (106 cells) or CF (3 X 105 cells) were plated and cultured on 6 well 
plates overnight and treated with 0.5 µM or 1 µM DOX for 3 h, and 24 h later, 
cells were scraped off and lysed with RIPA buffer.  The cell lysate was used for 
GSH derivatization and quantification of GSH and GSSG.  For GSH 
measurement, the supernatant was added to redox quenching buffer (20 mM HCl, 
5 mM diethylenetriaminepentaacetic acid, and 10 mM ascorbic acid) and then 
mixed with monobromobimane (MBB; prepared in HPLC-grade acetonitrile) 
derivatization buffer to yield final concentrations of 30 mM NaOH, 250 mM 
diethylenetriaminepenta acetic acid, and 2.5 mM MBB (Senft et al, 2000).  
Derivatization of GSH with MBB was carried out at 45°C for 15 min and the 
reaction stopped by addition of 0.6 N HCl.  GSSG was derivatized by the same 
method following pretreatment of the heart homogenate with 0.5 mM N-
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ethylmaleimide to conjugate free GSH and reduction of GSSG to GSH by 
addition of 5 mM dithiothreitol.  The MBB-derivatized samples were centrifuged 
and the supernatants assayed for thiol-bimane fluorescence by HPLC using a 
linear gradient from 0-100% solvent B (50% methanol and 0.25% acetic acid in 
water) in solvent A (10% methanol and 0.25% acetic acid in water) within 28 min 
at a flow rate of 0.8 mL/min with fluorescence detection at Ex370/Em485, detected 
with the Waters 2475 Multi λ fluorescence detector as described (Senft et al., 
2000).  Fluorescence intensities versus time of elution were quantified using 
Waters Breeze chromatography software v.3.2 (Waters Corporation, Milford, 
USA) and peak areas were integrated and converted to nmol equivalents 
according to the GSH standard curve.  
The redox potential (Eh) of the GSH/GSSG pool was determined in CM and 
CF culture.  It was calculated using the estimated cellular GSH and GSSG 
concentrations and the Nernst equation: Eh = Eo + (RT/nF) ln([GSSG] /[GSH]2).  
To estimate cellular concentrations, 1 mg of cell protein was assumed to be 
associated with 5 µl of cell volume (Mannery et al., 2010).  R is the gas constant, 
T is temperature, n is the number of electrons transferred, F is the faraday 
constant, and Eo = - 264 mV at a pH of 7.4. 
 
Immunoblot Assay 
Immunoblot assays were conducted as described in Chapter 3.  Antibodies 
were obtained as follows: rabbit anti-GCLc pAb (ab80841), rabbit anti-GCLm pAb 
(ab8144), and Rabbit anti-Nqo1 pAb(ab34173) from Abcam (Cambridge, MA), 
95 
 
mouse anti-catalase mAb (sc-271803), rabbit anti-Cu,Zn superoxide dismutase 
(Cu,ZnSOD) pAb ( sc-11407) from Santa Cruz Biotechnology (Santa Cruz, CA), 
rabbit anti-Mn superoxide dismutase (MnSOD) pAb from Upstate (Lake Placid, 
NY).  Rabbit anti-ECSOD pAb was a generous gift from Dr. Ladislav Dory, 
University of North Texas. 
  
Slot blot assay  
    CM and CF cell pellets were sonicated in a lysis buffer (0.32 Sucrose, 2mM 
EDTA, 2mM EGTA; 20mM HEPES) containing the protease inhibitors leupeptin 
(4 μg/mL), pepstatin (4 μg/mL), aprotinin (5 μg/mL), and PMSF (0.2 mM) with pH 
7.4 (measured at room temperature). Small amounts of homogenates (3 uL) 
were used to determine the total protein concentration by the BCA method 
(Pierce, Rockford, IL). For protein carbonyl determination, samples were 
derivatized with 2,4- dinitrophenylhydrazine (DNPH). For protein-bound HNE and 
3-NT, 3 uL of the homogenized sample was mixed and diluted with an equal 
volume of 12% SDS. Samples were further denatured with 10 μL of modified 
Laemmli buffer (0.125 M Trizma base, 4% SDS, and 20% glycerol) for 20 min at 
room temperature. Next, 250 ng of the derivatized protein was loaded in each 
slot (48-well slot format Bio-Dot SF apparatus with nitrocellulose membranes, 
pore size 0.45 μm, Bio-Rad, Hercules, CA, USA). The membranes were 
incubated with primary antibodies anti-3-NT pAb (from Life Technologies, 
Carlsbad, USA; dilution 1:2500), anti-protein-bound HNE pAb (from Alpha 
Diagnostic International, San Antonio, TX, USA; dilution 1: 500) or polyclonal 
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RbxDNP (from OxyBlot Protein Oxidation Detection Kit, Chemicon-Millipore, 
Billerica, MA, USA, dilution1:200) and goat 1:7500 anti-rabbit IgG (Sigma–Aldrich) 
antibody for the secondary detection. The antibody reaction was developed using 
5-bromo-4-chloro-3-indolyl phosphate in conjunction with nitroblue tetrazolium. 
The nitrocellulose membranes were dried overnight and scanned by photo 
scanner (Epson Perfection V600, Long Beach, CA, USA), and slot-blot line 
densities were quantified by the ImageQuant TL software package (GE 
Healthcare Bio-Sciences, Piscataway, NJ, USA). 
 
RNA extraction and real-time quantitative PCR (qRT-PCR) 
Total RNA extraction, cDNA preparation and qRT-PCR were conducted as 
described in Chapter 2.  The sequence of primers and Universal ProbeLibrary 
probe for specific genes are shown in Table 4.1.  
 
Statistical analysis 
All data are expressed as the mean ± SD or mean ± SE for n = 3 to 6 per group, 
as detailed in the Figure Legends.  In studies comparing two groups, statistical 
analysis was performed with the Student’s t-test.  In studies comparing multiple 
groups to the same control group, statistical analysis was performed with one-
way ANOVA followed by Dunnett's post-test.  In studies comparing more than 
two groups, statistical analysis was performed with one-way ANOVA followed by 
Newman-Keuls multiple comparison test. 
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Results 
DOX treatment increases GS-HNE level in mouse heart tissue 
DOX initiates ROS and causes lipid peroxidation, while HNE is the one of the 
major toxic lipid metabolites.  The highly electrophilic HNE reacts rapidly with 
nucleophiles, particularly GSH, to form GS-HNE, which is a substrate of Mrp1.   
Here, the retention of GS-HNE was characterized in WT and Mrp1-/- mouse 
heart tissue following chronic DOX treatment (2 mg/kg).   As shown in Figure 4.1, 
chronic DOX treatment increased GS-HNE levels in WT and Mrp1-/- mouse heart 
at 48 h (Figure 4.1A) and 2 weeks (Figure 4.1B) after the last DOX treatment.  
The increase was statistically significant only at 2 weeks, but not 48 h after the 
last DOX treatment.  However, in contrast to our expectations, there was no 
significant difference in GS-HNE levels between genotypes.  
 
GSH and GSSG levels in mouse heart tissue 
    As GSH and GSSG are known substrates for Mrp1, we investigated whether 
loss of Mrp1 would alter GSH and GSSG levels in the cell, and therefore disrupt 
the balance of the GSH/GSSG redox couple.  In the in vivo study, GSH and 
GSSG level were examined in mouse heart 48 h and 2 weeks after the last dose 
of DOX in the chronic treatment.  DOX treatment significantly decreased both 
GSH and the GSH/GSSG ratio at 48 h, indicating DOX-induced oxidative stress 
(Figure 4.2A).  GSH and GSH/GSSG returned to control levels two weeks later, 
at the end of the recovery period (Figure 4.2B).  Although there was no 
significant difference in the GSH/GSSG ratio between WT and Mrp1-/- mice at 
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either time point, it is interesting to note the significantly higher basal (saline 
treatment) levels of GSH and GSSG in Mrp1-/- compared to WT mouse heart.  
GSSG levels were also significantly increased in Mrp1-/- vs WT mice following 
DOX treatment at both time points.  This observation is consistent with the 
function of Mrp1 to efflux GSH and GSSG.  
 
GSH and GSSG measurement in CM and CF 
    The intracellular GSH and GSSG levels in CM and CF culture were also 
assessed.  Consistent with our findings in treatment-naïve and saline-treated 
mice, untreated CM and CF derived from Mrp1-/- mice had significantly higher 
GSH and GSSG levels compared to WT cells (Figure 4.3).  However, no 
difference in the GSH/GSSG ratio was observed between genotypes.  This 
question was further investigated in DOX treated cells.  In preliminary studies, 
the time course of the changes in GSH and GSSG in cells following DOX 
treatment was examined.  CM were treated with saline or DOX, and intracellular 
GSH and GSSG examined at various times over 24 h.  As shown in Figure 4.4, 
the GSH level decreased and the GSSG level increased rapidly in both WT and 
Mrp1-/- CM within 15 min after addition of DOX.  Over the next 24 h, GSH and 
GSSG levels gradually returned to basal levels in WT CM.  However, GSH and 
GSSG levels continuously increased and remained at a higher level in Mrp1-/- 
cells.  Subsequent studies characterized GSH and GSSG levels at the 15 min, 
30 min and 24 h time points after treatment with DOX.  At 15 min and 30 min 
after DOX treatment, GSH levels decreased and GSSG levels increased in both 
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WT and Mrp1-/- CMs.  Thus, the GSH/GSSG ratio (Figure 4.5A) of the 
GSH/GSSG pool decreased and the redox potential (Eh) (Table 4.2) became 
less negative in DOX treated cells.  However, GSH and GSSG levels in Mrp1-/- 
cells were significantly increased 24 h after DOX treatment, but were not different 
in WT cells (Figure 4.6A).  As a consequence, the GSH/GSSG ratio and the 
redox potential (Eh) of the GSH/GSSG pool did not change in either genotype 
with either treatment (Table 4.3).  Similar effects were observed in CF cultures 
(Figure 4.5B and 4.6B). 
 
Expression of GSH biosynthesis enzymes  
    The increase in GSH levels after DOX treatment in Mrp1-/- cells could be due 
to decreased GSH efflux, increased GSH biosynthesis or increased recycling 
from GSSG.  Thus, the mRNA and protein expression levels of GSH biosynthesis 
enzymes and GSH reductase (GR) were examined.  As shown in Figure 4.7A, 
DOX treatment significantly increased both mRNA and protein expression of 
GCLc, GCLm, and glutathione synthetase (GSS) at 24 h in Mrp1-/- CM, but had 
no effects in WT CM.  DOX treatment had no effect on GR protein expression in 
either genotype (data not shown).  Similar results were observed in CF (Figure 
4.7B).  These data indicate that the higher level of GSH in DOX treated Mrp1-/- 
cells could be at least partly due to the increased expression of GSH 
biosynthesis enzymes, and a subsequent higher rate of GSH synthesis.  
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Protein expression of antioxidant enzymes  
    The expression of important antioxidant enzymes were exmined, and showed 
that in both CM and CF, DOX slightly increased protein expression of catalase, 
Cu,ZnSOD and MnSOD in both genotypes, but these changes were not 
statistically significant (Figure 4.8).  However, the mRNA and protein expression 
of SOD3 was decreased in Mrp1-/- CM compared to WT CM after saline 
treatment (64 ± 2% of WT mRNA level, p < 0.05, 62 ± 8% of WT protein level, p 
< 0.05) (Figure 4.9A).  DOX treatment significantly decreased the expression of 
SOD3 in both WT and Mrp1-/- CM, such that SOD3 expression was still lower in 
Mrp1-/- CM (46 ± 5% of WT mRNA level, p < 0.05, 43 ± 12 % of WT protein level, 
p < 0.05).  Interestingly, this difference in SOD3 between genotypes was not 
observed in CF (Figure 4.9B).  The mRNA expression of glutathione peroxidase 
(Gpx), glutathione S-transferase (GST) and NAD(P)H dehydrogenase, quinone 1 
(NQO1), heme oxygenase 1 (HO-1) were also detected and  DOX increased 
expression of GPx1, GPx3, GSTM1 and GSTM2 in both WT and Mrp1-/- CM and 
CF, but there was no difference between genotypes (Figure 4.10).  However, 
mRNA and protein expression of Nqo1 was higher and HO-1 mRNA expression 
was significantly elevated in Mrp1-/- vs WT CM and CF after DOX treatment 
(Figure 4.11). 
 
Protein oxidative damage in DOX treated CM and CF 
Protein oxidative damages in CM and CF were also detected culture including 
HNE-protein adducts, 3 nitrotyrosine-protein adducts and protein carbonyl levels.  
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Although we expected that the oxidative stress induced by DOX would increase 
these measures of protein oxidative damages, within 30 min after the DOX 
treatment, these protein oxidative damage markers just slightly increased in DOX 
treated cell culture in both genotype.  However, these increases were not 
statistically significant.  There was no obvious difference observed between WT 
and Mrp1-/- cells (Figure 4.12).  Similar results were obtained in samples 
collected 24 h after DOX treatment.  
 
Discussion 
Changes in HNE formation and GSH/GSSG homeostasis are two important 
consequences of oxidative stress.  Since GS-HNE, GSH and GSSG are all 
substrates of Mrp1, we hypothesized that loss of Mrp1 would change the efflux of 
these molecules and potentially cause abnormal cellular responses to oxidative 
stress.  This chapter explores the effects of Mrp1 on redox status in mouse heart 
as well as in CM and CF culture.  Measurements conducted included levels of 
intracellular GS-HNE, GSH and GSSG as well as expression of antioxidant 
enzymes and protein oxidative damage. 
 An increase in HNE and HNE adducted protein are detected in heart tissues 
as early as 3 hr following DOX administration (Luo et al., 1997; Liu and Tan, 
2003; Chaiswing et al., 2004).  Further, sarcolemmal membrane vesicles from 
Mrp1-/- mouse are unable to transport GS-HNE, indicating that Mrp1 is the only 
ATP dependent efflux transporter of GS-HNE in the mouse heart (Jungsuwadee 
et al., 2006; Jungsuwadee et al., 2012).  Here, chronic DOX treatment increased 
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GS-HNE in the mouse heart, indicating that DOX-induced oxidative stress.  It 
was anticipated that the loss of Mrp1 would eliminate the efflux of GS-HNE and 
cause its intracellular accumulation.  However, there was no significant difference 
in the GS-HNE concentration between WT and Mrp1-/- mice heart.  These data 
imply a complex adaptation in Mrp1-/- mice.  To protect macromolecules from 
modification or adduction by HNE, mammalian cells metabolize HNE rapidly.  In 
addition to conjugation with GSH to yield GS-HNE, HNE metabolism includes 
reduction to the corresponding alcohol, 1,4-dihydroxy-2-nonene (DHN) or 
oxidation to the corresponding acid, 4-hydroxy-2-nonenoic acid (HNA) (Alary et 
al., 2003; Volkel et al, 2005).  The loss of GS-HNE efflux may saturate these 
metabolic pathways, but can also lead to metabolism of GS-HNE via an NADH-
dependent alcohol dehydrogenase (ADH)-catalyzed reduction to GS-DHN and/or 
aldehyde dehydrogenase-catalyzed oxidation to GS-HNA.  The biological 
activities of these GSH conjugates are not yet well characterized nor has their 
cellular efflux by Mrp1 been described (Dalleau et al., 2013; Frohnert and 
Bernlohr, 2014).  We did not measure these additional HNE metabolic products, 
thus we cannot conclude whether loss of Mrp1 alters HNE metabolism in mouse 
heart.  
One of the mechanisms whereby cells maintain their redox status is by 
maintaining the GSH/GSSG ratio.  Since Mrp1 can transport both GSH and 
GSSG, we hypothesized that loss of Mrp1 would disrupt the GSH/GSSG balance.  
In our chronic treatment mouse model, GSH and the GSH/GSSG ratio decreased 
at 48 h after the last dose of DOX.  In CM and CF culture, GSH and the 
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GSH/GSSG ratio decreased very quickly, within 15 min of DOX addition.  
Although as an indicator of intracellular oxidative stress, the GSH/GSSG ratio 
was similar between WT and Mrp1-/- mice heart and cell culture, the GSH and 
GSSH levels were always higher in Mrp1-/- mice hearts and Mrp1-/- cells 
compared to WT.  This is consistent with our previous finding that treatment-
naïve Mrp1-/- mice heart had significantly higher GSH compared to WT mice, as 
well as to other group’s finding regarding the effects of Mrp1 on the intracellular 
GSH level.  
    A major determinant of cellular GSH homeostasis is GCL, which catalyzes the 
first and rate-limiting step in de novo synthesis of GSH from glutamate and 
cysteine.  Its activity is controlled by a complex regulation at several levels, 
including transcriptional activation by oxidative stress, reversible formation of a 
disulfide bond between its two subunits (GCLc and GCLm), and the feedback 
inhibition by GSH (Richman et al., 1975; Huang et al., 1993; Fraser et al., 2003; 
Franklin et al., 2009).  in this study, even in the absence of a significant 
difference in GCLc and GCLm expression, the treatment-naïve Mrp1-/- mice 
heart and saline treated Mrp1-/- cells exhibited higher GSH compared to WT 
mice heart and cells.  These data indicate the important role of Mrp1-mediated 
efflux in intracellular GSH regulation.  Although it is known that GCL activity is 
feedback-inhibited by GSH, we did not measure GCL activity so do not know the 
extent of feedback inhibition in treatment-naïve Mrp1-/- cells.  We also found that 
DOX increased concentrations of GSH and GSSG in Mrp1-/- cells but not WT 
cells; however, the redox potential (Eh) of the GSH/GSSG pool was similar 
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between genotypes.  To test whether this increased GSH pool was due to 
increased GSH synthesis, the expression of GSH synthesis enzymes GCLc, 
GCLm and GSS were examined.  After DOX treatment, Mrp1-/- cells have 
significantly higher expression of GCLc and GCLm at both mRNA and protein 
levels compared to WT cells.  The expression of GCLc, GCLm and GSS are all 
known to respond to oxidative stress and all three genes are upregulated by Nrf2 
pathway activation at the transcription level.  In this study, the expression of 
NQO1 and HO-1, two typical downstream genes of the Nrf2 pathway, were 
significantly higher in DOX treated Mrp1-/- cells vs WT cells.  These data 
indicated that the greater Nrf2 pathway activation caused increased expression 
of GCLc and GCLm in Mrp1-/- cells.  We did not measure GCL activity in DOX 
treated cells, and we do not know whether enzyme activity was inhibited by the 
high level of GSH in Mrp1-/- cells. We speculate that such feedback inhibition 
occurred, but was not sufficient to decrease the overall GSH synthesis rate 
because of the enhanced expression of the GCL enzymes which were 
upregulated at the transcription level.  Thus, the feedback inhibition of GCL 
activity by GSH is not the major determinant of GSH levels in DOX treated Mrp1-
/- cells.  Taken together, these results suggest that despite comparable Eh for 
GSH/GSSG in WT and Mrp-/- cells, the oxidative stress Mrp1-/- cells suffer 
stimulates the Nrf2 signaling pathway, causing the upregulation of the GSH 
synthesis enzymes at the transcriptional level.  Importantly, the higher 
intracellular GSH level and the increase of GCLc and GCLm expression still 
cannot protect the Mrp1-/- cell from DOX-induced cytotoxicity.  
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Recently, an emerging concept, reductive stress, may provide some clue 
regarding why the higher GSH level could not rescue Mrp1-/- cells from DOX 
toxicity (Narasimhan et al., 2015).  There are increasing examples of excessive 
amounts of reducing equivalents, in the forms of NAD(P)H and/or GSH, resulting 
in cellular dysfunction and cardiac disease (Narasimhan et al., 2015, Brewer et 
al., 2012).   Zhang et al. (2010) reported that overexpression of heat shock 
protein HSP2 leads to an increased ratio of GSH/GSSG, and a decrease of ROS, 
yet resulted in cardiomyopathy.  The human mutant αB-crystallin overexpression 
mouse model characterized by Rajasekaran et al. (2007; 2011) shows sustained 
activation of the Nrf2 signaling pathway, increases in GSH and the GSH/GSSG 
ratio, and hypertrophic cardiomyopathy.  Involvement of reductive stress is 
further demonstrated by the fact that quenching of reducing power rescued the 
mice from heart failure (Rajasekaran et al., 2007; Rajasekaran et al., 2011).  The 
more recent study indicates that GSH-induced reductive stress is causally linked 
to mitochondrial oxidation and cytotoxicity, with the mechanism not fully 
understood (Zhang et al., 2012).  In our study, compared to WT cells, Mrp1-/- 
cells had significantly higher GSH and GSSG after saline treatment and even 
higher after DOX treatment.  This is a little surprising since we expected the 
change of GSH and GSSG level elicited by DOX would return to pretreatment 
levels after the appropriate antioxidant cellular response had taken effect.  
However, we saw sustained activation of Nrf2 signaling and upregulation of GSH 
synthesis enzymes in DOX treated Mrp1-/- cells.  We postulate that in DOX-
treated Mrp1-/- cells, the normal redox signaling activation and compensatory 
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responsiveness are disrupted and lead to cytotoxic consequences.  However, we 
did not observe any structural or functional tissue injury in saline treated Mrp1-/- 
mice heart (Deng et al., submitted).  Thus, it is unlikely that reductive stress is a 
major contributor to the observed cardiac injury after DOX.  Other measurements, 
including NADPH/NADP, a battery of antioxidant enzymes and oxidative stress 
markers, need to be assessed before making any conclusions regarding the role 
of reductive stress in Mrp1-/- mice heart.   
    In this study, we did not measure the extracellular GSH concentration, which 
may serve to protect the interstitium from oxidants.  If the loss of Mrp1 impairs 
GSH efflux, loss of extracellular GSH may also accelerate oxidative damage in 
the extracellular environment.  In addition, the extracellular GSH can be broken 
down in the extracellular space by γGT and dipeptidase, thus producing cysteine.  
The lower extracellular GSH concentration could affect the cysteine/cystine 
balance, which is also critical for maintaining extracellular redox status (Levonen 
et al., 2004).  For example, extracellular GSH has been shown to offer 
neuroprotection against methyl mercury toxicity in a manner dependent on 
MRP1-mediated efflux (Rush et al. 2012).  To test the importance of extracellular 
GSH in CM and CF culture, exogenous non-cell penetrable GSH was added in 
the medium and compared the cell survival following DOX treatment.  The 
exogenous GSH reduced the cell death in WT and Mrp1-/- cells, with 10 mM 
GSH eliminating the difference of cell viability between WT and Mrp1-/- cells 
(Figure 4.10).  This means that the lower GSH in the extracellular environment 
could contribute to the DOX sensitivity in Mrp1-/- cells.  
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    Furthermore, the significance of GSSG, which is also transported by MRP1, 
cannot be overlooked, given its cytotoxicity.  The increased intracellular GSSG 
concentration by microinjection or inhibition of the efflux through Mrp1 has been 
shown to cause glutathionylation of cysteine-containing proteins, resulting in 
damaged protein function, finally causing cell death (Park et al., 2009).  Whether 
this could happen in Mrp1-/- mouse heart is not known.  All these possibilities 
need to be confirmed by more studies.  
    Numerous studies have shown that GSH depletion is a common feature of 
apoptosis induced by a variety of stress.  GSH depletion has been associated 
with apoptosis either by predisposing cells to apoptosis or by modulating 
mitochondrial membrane potential and subsequent activation of caspases 
(Armstrong et al., 2002).  GSH depletion could be mediated through its oxidation 
to GSSG by ROS, the efflux through GSH transporters or the loss of membrane 
integrity (Circu et al., 2008; Franco et.al, 2007; Ghibelli et al., 1998; Hammond et 
al., 2004).  Several studies have shown that prevention of GSH efflux could 
attenuate or prevent apoptosis (Ghibelli et al., 1998; He et al., 2003; Circu et al., 
2009).  However, conflicting results exist regarding the identity of the specific 
transporter involved in GSH depletion.  Several studies have suggested a role for 
MRP1 in GSH depletion (Mueller et al., 2005; Hammond et al., 2007; Laberge et 
al., 2007; Sreekumar et al., 2012).  In contrast to those studies, other groups 
demonstrated that inhibition of MRP1-mediated transport accelerates apoptosis 
and GSH loss (Franco et al., 2007; Franco et al., 2014).  The discrepancy among 
these studies could be due to differences in cell types, cell culture conditions, 
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levels of MRP1 expression, duration of the stress, the stimulus used to induce 
apoptosis and GSH levels maintained during experimentation among various 
studies.  In our experiment, in the absence of Mrp1-mediated GSH efflux, the 
Mrp1-/- cells were still more sensitive to DOX toxicity demonstrated as less cell 
survival and more apoptosis compared to WT cells.  Thus, GSH efflux mediated 
by Mrp1 is not essential and not the major determinant of DOX-induced 
apoptosis in CM and CF.    
Another very important finding is that there was less ECSOD/SOD3 
expression in Mrp1-/- CM compared to WT CM with either saline or DOX 
treatment.  Among the three SOD isoforms (Cu,ZnSOD, MnSOD2 and ECSOD), 
ECSOD is the sole enzyme that is located in the extracellular matrix.  It catalyzes 
the dismutation of •O2
- to H2O2 and O2, and maintains relatively low levels of O2
•- 
in the extracellular environment.  Overexpression of ECSOD in heart tissue or 
ECSOD administration in animal models has been shown to attenuate oxidative 
stress and to mitigate tissue dysfunction in cardiovascular disease mimetics (Li et 
al., 2001; Li et al., 1998; Wahlund et al., 1992).  Cardiac-specific ECSOD 
overexpression attenuates ROS levels and increases NO bioavailability in 
response to ischemia/reperfusion, thus protecting against reperfusion injury 
(Obal et al., 2012).  In contrast, lack of ECSOD leads to increases in myocardial 
apoptosis and significantly more left ventricle fibrosis in mice treated with DOX 
(Kliment et al, 2009).  These data suggest that the lower ECSOD expression in 
Mrp1-/- CM contributes to the greater sensitivity of CM to DOX.  However, the 
mechanism by which loss of Mrp1 decreases ECSOD expression remains 
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unclear.  An earlier study reported that treatment of two fibroblast lines with a 
wide concentration range of oxidizing agents uniformly, dose-dependently and 
continuously reduced ECSOD expression in a manner coordinated by cytokines, 
rather than as a response of individual cells to oxidants (Strålin and Marklund, 
1994).  It is thus possible that the loss of Mrp1 places the cells under oxidative 
stress, which in turn changes the cytokine regulation, and finally impairs the 
expression of ECSOD.  In addition, Reddy et al. (2007) reported that type II 
alveolar epithelial cells derived from Nrf2-/- mice show significantly higher SOD3 
mRNA expression compared to WT cells, while GSH supplementation in Nrf2-/- 
cells decreases the SOD3 expression down to the level of WT cells.  These data 
are consistent with the Nrf2 activation, higher GSH level and lower SOD3 
expression observed in Mrp1-/- CM.  However, to further test whether oxidative 
stress, Nrf2 activation or the high level of GSH caused the lower expression of 
SOD3 in Mrp1-/- CM, we need to treat the CM with other oxidizing agents to see 
if they cause similar effects as DOX, or we could deplete the GSH in CM culture 
to see if it removes the difference of SOD3 expression between genotypes.  
Taken together, loss of Mrp1 lead to lower expression of SOD3 and it may 
contribute to the sensitivity of Mrp1-/- CM to DOX toxicity.  
It is worth noting that the difference in SOD3 expression between genotypes 
was only found in CM but not CF.  It indicates that distinct regulation of SOD3 
gene exist in these two cell types.  The different response of SOD3 gene 
expression to DOX treatment in CM and CF are further studied and discussed in 
the next chapter (Chapter 5).   However it is still largely unknown why loss of 
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Mrp1 only deceases SOD3 expression in CM but not CF, how these ECSOD 
produced by these two cell types coordinate with each other and how these 
ECSOD proteins from different sources contribute to the DOX-induced 
pathological changes in the heart.  Studies focusing on these questions will be 
very helpful to identify the function of SOD3 in specific cell components of heart.   
    In summary, the key findings of this study are that loss of Mrp1 caused an 
increase of intracellular GSH and GSSG in both mouse heart and CM/CF culture.  
Following DOX treatment, the increased GSH pool in Mrp1-/- CM and CF is due 
to the loss of Mrp1-mediated efflux as well as the increased GSH synthesis.  This 
study shows that retention of intracellular GSH does not inhibit further GSH 
synthesis in Mrp1-/- cells, thus providing important information regarding the 
dynamics of Mrp1 in regulating cellular GSH levels.  Since the role of GSH in 
maintaining redox status is well understood, these data highlight the potential 
role of Mrp1 in oxidative stress regulation.  In addition, the effects of Mrp1 on 
extracellular antioxidant defense systems, such as the extracellular GSH pool 
and ECSOD, open a new field of study of Mrp1’s function that merits further 
investigation.   
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Figure 4.1. Concentration of GS-HNE in heart tissue.  Mice were treated with 
protocol B (2 mg/kg DOX each time, twice a week for 5 weeks), and GS-HNE 
concentration in heart was measured by LC-MS/MS 48 h (A) or 2 weeks (B) after 
the last dose of saline or DOX.  Each bar represents the mean ± SE. (n = 5 for 
saline treated group; n = 6 for DOX treated group.  *, p < 0.05 DOX vs. saline of 
the same genotype by Newman-Keuls multiple comparison test after one-way 
ANOVA.) 
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Figure 4.2. Assessment of GSH, GSSG and the GSH/GSSG ratio in mouse 
heart. Mice were treated with protocol B (2 mg/kg DOX each time, twice a week 
for 5 weeks), and GSH and GSSG concentrations measured by HPLC at 48 h (A) 
or 2 weeks (B) after the last dose of DOX.  Each bar represents the mean ± SE 
(n = 6, *, p < 0.05 DOX vs. saline of the same genotype; #, p < 0.05 vs. 
respective WT mice by Newman-Keuls multiple comparison test after one-way 
ANOVA).  
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Figure 4.3. Concentration of GSH and GSSG, and the GSH/GSSG ratio in 
untreated CM (A) and CF (B). GSH and GSSG were measured by HPLC.  
Significantly higher basal levels of GSH and GSSG were observed in Mrp1-/- 
cells compared to WT cells so that there was no difference in GSH/GSSG ratio 
between genotypes.  Each bar represents the mean ± SD (n = 3, * p < 0.01 by 
Welch’s t- test) 
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Figure 4.4. Dynamic changes of GSH, GSSG level, and the GSH/GSSG ratio 
in CM and CF.  CM (A) and CF (B) were treated with saline or DOX (0.5 µM in 
CM and 1 µM in CF) for 3 h, then the saline or DOX containing medium was 
removed and cells were incubated in fresh medium.  GSH and GSSG were 
measured by HPLC at the indicated times after the addition of DOX.  Data 
represent results from one preparation of cells.  
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Figure 4.5. Concentration of GSH and GSSG, and the GSH/GSSG ratio at 15 
min and 30 min after DOX treatment in CM and CF. CM (A) and CF (B) were 
treated with saline or DOX (0.5 µM in CM and 1 µM in CF).  Fifteen min or thirty 
min later, cell were harvested and GSH and GSSG were measured by HPLC. 
Each bar represents the mean ± SD (n = 3; *, p < 0.05 DOX vs. 0 min of the 
same genotype; #, p < 0.05 Mrp1-/- vs. respective WT cells by Newman-Keuls 
multiple comparison test after one-way ANOVA) 
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Figure 4.6. Concentration of GSH and GSSG, and the GSH/GSSG ratio at 24 
h after saline or DOX treatment in CM and CF. CM (A) and CF (B) were 
treated with saline or DOX (0.5 µM in CM and 1 µM in CF) for 3 h, then the saline 
or DOX containing medium was removed and cells were incubated in fresh 
medium for another 24 h, at which time GSH and GSSG were measured by 
HPLC.  Each bar represents the mean ± SD (n = 3; *, p < 0.05 DOX vs. saline of 
the same genotype; #, p < 0.05 Mrp1-/- vs. respective WT cells by Newman-
Keuls multiple comparison test after one-way ANOVA) 
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Figure 4.7A. Quantitative analysis of GCLc, GCLm, and GSS expression in 
CM. CM were treated with saline or 0.5 µM DOX for 3 h, then the saline or DOX 
containing medium removed and cells incubated in fresh medium for another 24 
h.  The blots are representative of one of 3 independent experiments.  Each bar 
represents the mean ± SD. (*, p < 0.05 DOX vs. saline of the same genotype; #, 
p < 0.05 Mrp1-/- vs. respective WT cells by Newman-Keuls multiple comparison 
test after one-way ANOVA. GCLc (glutamate-cysteine ligase, catalytic subunit), 
GCLm (glutamate--cysteine ligase, regulatory subunit), and GSS (glutathione 
synthetase). 
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Figure 4.7B Quantitative analysis of GCLc, GCLm, and GSS expression in 
CF.  CF were treated with saline or 1 µM DOX for 3 h, then the saline or DOX 
containing medium removed and cells incubated in fresh medium for another 24 
h.  The blots are representative of one of 3 independent experiments.  Each bar 
represents the mean ± SD. (*, p < 0.05 DOX vs. saline of the same genotype; #, 
p < 0.05 Mrp1-/- vs. respective WT cells by Newman-Keuls multiple comparison 
test after one-way ANOVA.  GCLc, glutamate-cysteine ligase, catalytic subunit; 
GCLm, glutamate--cysteine ligase, regulatory subunit; GSS, glutathione 
synthetase. 
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Figure 4.8A. Quantitative analysis of antioxidant enzymes expression in CM. 
CM were treated with saline or 0.5 µM and 1 µM DOX for 3 h, the saline or DOX 
containing medium removed and cells incubated in fresh medium for another 24 
h.  Protein expression was detected by Western blot.  The blots are 
representative of one of 3 independent experiments.  Each bar represents the 
mean ± SD.  
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Figure 4.8B. Quantitative analysis of antioxidant enzymes expression in CF. 
CF were treated with saline or 1 µM and 3 µM DOX for 3 h, the saline or DOX 
containing medium removed and cells incubated in fresh medium for another 24 
h.  Protein expression was detected by Western blot.  The blots are 
representative of one of 3 independent experiments.  Each bar represents the 
mean ± SD.  
 
B 
121 
 
 
     
 
     
 
Figure 4.9. Quantitative analysis ECSOD expression in CM and CF. CM (A) 
and CF (B) were treated with saline or DOX (0.5 µM in CM and 1 µM in CF) for 3 
h, the saline or DOX containing medium removed and cells incubated in fresh 
medium for another 24 h.  mRNA expression was detected by Real-Time PCR 
and protein expression was detected by Western blot.  The blots are 
representative of one of 3 independent experiments.  Each bar represents the 
mean ± SD. (*, p < 0.05 DOX vs. saline of the same genotype; #, p < 0.05 Mrp1-
/- vs. respective WT cells by Newman-Keuls multiple comparison test after one-
way ANOVA) 
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Figure 4.10A. Quantitative analysis of GPx1, GPx3, GSTM1 and GSTM2 
mRNA expression in CM. CM were treated with saline or 0.5 µM DOX for 3 h, 
then the saline (SAL) or DOX containing medium removed and cells incubated in 
fresh medium for another 24 h.  mRNA expression was detected by Real - Time 
PCR.  Each bar represents the mean + SD. (n = 3; *, p < 0.05 DOX vs. saline of 
the same genotype; #, p < 0.05 Mrp1-/- vs. respective WT cells by Newman-
Keuls multiple comparison test after One-way ANOVA) GPx, glutathione 
peroxidase; GST, glutathione S-transferase; 
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Figure 4.10B. Quantitative analysis of GPx1, GPx3. GSTM1 and GSTM2 
mRNA expression in CF.  CF were treated with saline or 1 µM DOX for 3 h, 
then the saline (SAL) or DOX containing medium removed and cells incubated in 
fresh medium for another 24 h.  mRNA expression was detected by Real - Time 
PCR.  Each bar represents the mean + SD. (n = 3; *, p < 0.05 DOX vs. saline of 
the same genotype; #, p < 0.05 Mrp1-/- vs. respective WT cells by Newman-
Keuls multiple comparison test after One-way ANOVA) GPx, glutathione 
peroxidase; GST, glutathione S-transferase; 
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Figure 4.11. Quantitative analysis of Nqo1 and HO-1 mRNA and protein 
expression in CM and CF. CM (A and C) and CF (B and D) were treated with 
saline or DOX (0.5 µM in CM and 1 µM in CF) for 3 h, the saline (SAL) or DOX 
containing medium removed and cells incubated in fresh medium for another 24 
h.  mRNA expression was detected by Real-Time PCR and protein expression 
was detected by Western blot.  The blots are representative of one of 3 
independent experiments.  Each bar represents the mean ± SD. (n = 3; *, p < 
0.05 DOX vs. saline of the same genotype; #, p < 0.05 Mrp1-/- vs. respective WT 
cells by Newman-Keuls multiple comparison test after One-way ANOVA) 
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Figure 4.12A. Protein oxidative damage in CM.  CM were treated with saline 
or 1 or 5 µM DOX for 30 min.  Then, HNE-protein adducts, 3-nitrotyrosine-protein 
adducts and protein carbonyl levels were assessed by slot-blot assay.  NT, 3-
nitrotyrosine-protein adducts; PC, protein carbonyl.  Each bar represents the 
mean + SE. (n = 3) 
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Figure 4.12B. Protein oxidative damage in CF.  CF were treated with saline or 
2 or 5 µM DOX for 30 min.  Then, HNE-protein adducts, 3-nitrotyrosine-protein 
adducts and protein carbonyl levels were assessed by slot-blot assay.  NT, 3 
nitrotyrosine-protein adducts; PC, protein carbonyl.  Each bar represents the 
mean + SE. (n = 3) 
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Figure 4.13. Exogenous GSH rescued Mrp1-/- CM and CF. CM (A) and CF (B) 
were cultured on a 96-well plate for 48 h before treatment with saline or DOX for 
3 h. Tetrazolium reduction was measured 48 h after DOX removal.  Varying 
concentrations of GSH were added to the medium during DOX treatment and 
after removal of DOX. Only addition of 10 mM GSH eliminated the difference in 
cell viability between WT and Mrp1-/- cells.  Each bar represents the mean ± SD. 
(n = 6, *, p < 0.05 by Newman-Keuls multiple comparison test after One-way 
ANOVA) 
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Table 4.1. Primers and Universal ProbeLibrary probes used for qRT-PCR  
 
 
 
 
 
 
 
 
GPx, glutathione peroxidase; GSS, glutathione synthetase; GST, glutathione S-transferase; HO-1: heme oxygenase 1; 
NQO1, NAD(P)H dehydrogenase, quinone 1; GCLc, glutamate-cysteine ligase catalytic subunit; GCLm, glutamate-
cysteine ligase regulatory subunit; Mrp1, multidrug resistance-associated protein 1; SOD3, superoxide dismutase 3. 
Genes Forward primer (5 ׳3-׳ ) Reverse primer (5 ׳3-׳ ) Universal Probe Library probe 
18S rRNA gcaattattccccatgaacg gggacttaatcaacgcaagc #48 
GPx1 tttcccgtgcaatcagttc tcggacgtacttgagggaat #2 
GPx3 ggcttcccttccaaccaa cccacctggtcgaacatact #92 
GSS agatggctacatgcccagtc gcacgagatctctctagcatca #48 
GSTM1 gcagctcatcatgctctgtta tttctcagggatggtcttcaa #106 
GSTM2 agttggccatggtttgctac agcttcatcttctcagggagac #106 
GCLc ctgcacatctaccacgcagt gaacatcgcctccattcagt SYBR green 
GCLm tgactcacaatgacccgaaa tcaatgtcagggatgctttct #108 
HO-1 aggctaagaccgccttcct tgtgttcctctgtcagcatca #17 
NQO1 agcgttcggtattacgatcc agtacaatcagggctcttctcg #50 
SOD3 ctcttgggagagcctgaca gccagtagcaagccgtagaa #102 
1
2
8
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Table 4.2: Redox potential (Eh) of the GSH/GSSG pool in CM and CF  
(15 min and 30 min) 
 
 
The redox potential (Eh) of the GSH/GSSG pool in CM and CF at 15min and 30 
min after DOX treatment.  CM and CF were treated with DOX (0.5 µM in CM and 
1 µM in CF) for 0, 15 and 30 min.  Eh is calculated by the Nernst equation, Eh = 
Eo + (RT/nF) ln([GSSG] /[GSH]2). To estimate cellular concentrations, 1 mg of 
cell protein was assumed to be associated with 5 µl of cell volume (Mannery et 
al., 2010).  R is the gas constant, T is temperature, n is the number of electrons 
transferred, F is the faraday constant, and Eo = - 264 mV at a pH of 7.4.  Data 
are presented as mean ± SD (n = 3; *, p < 0.05 DOX vs. 0 min of the same 
genotype by Dunnett's post-test after one-way ANOVA) 
 
 
  
 Eh of GSH/GSSG (mV) 
Ave ± SD 
Cell Mice Treatment 
  0 min DOX 15 min DOX 30 min 
CM WT -237.7 ±2.3 -231.4± 0.8 * -232.8± 2.6 * 
Mrp1-/- -240.6±1.6 -234.8±2.3 * 233.0± 3.0 * 
CF WT -236.5±1.3 -230.0±5.4 230.5± 3.5 
Mrp1-/- -239.4 ±2.5 -235.4 ±2.2 234.9± 1.9 
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Table 4.3: Redox potential (Eh) of the GSH/GSSG pool in CM and CF  
(24 h) 
 
 
 
 
 
 
 
 
 
 
The redox potential (Eh) of the GSH/GSSG pool in CM and CF after saline or 
DOX treatment.  CM and CF were treated with saline or DOX (0.5 µM in CM and 
1 µM in CF) for 3 h, the saline or DOX containing medium removed and cells 
incubated in fresh medium for another 24 h.  Eh is calculated by the Nernst 
equation, Eh = Eo + (RT/nF) ln([GSSG] /[GSH]2).  To estimate cellular 
concentrations, 1 mg of cell protein was assumed to be associated with 5 µl of 
cell volume (Mannery et al., 2010).  R is the gas constant, T is temperature, n is 
the number of electrons transferred, F is the faraday constant, and Eo = - 264 
mV at a pH of 7.4. Data are presented as mean ± SD, n = 3. 
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 Eh of GSH/GSSG (mV) 
Ave ± SD 
Cell Mice Treatment 
  saline DOX 
CM WT -234.6 ±1.6 -229.1± 7.0 
Mrp1-/- -234.8 ±2.7 -236.5 ±1.2 
CF WT -235.4 ±3.0 -235.0±2.1 
Mrp1-/- -237.7 ±1.0 -237.2 ±4.5 
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Chapter Five 
 
The effect of DOX on expression of ECSOD/SOD3 in CM and CF 
 
Introduction  
    Three forms of SOD exist in mammalian tissues: Cu,ZnSOD/SOD1, 
MnSOD/SOD2 and ECSOD/SOD3.  While Cu/Zn SOD is localized in cytosol, and 
MnSOD in mitochondria, the ECSOD is the only SOD secreted into the 
extracellular environment.  It catalyzes the dismutation of •O2
- to H2O2 and O2, 
and maintains relatively low levels of •O2
- in the extracellular environment.  Due 
to its special cellular localization, it has unique and irreplaceable roles in 
maintaining the normal redox status in tissue.  
 
SOD structure characteristics 
    The ECSOD/SOD3 gene has been mapped to human chromosome 4 and 
mouse chromosome 5 and share 60% identity.  In most species, ECSOD exists 
as a 135 KDa homotetramer composed of two disulfide-linked dimers.  As shown 
in Figure 5.1, each subunit has a molecular weight of 24 KD and is composed of 
(1) an amino-terminal signal peptide, which permits its secretion from the cell; (2) 
an active domain binding copper and zinc with a strong homology with 
Cu,ZnSOD; (3) a heparin-binding domain, which is a C-terminal domain 
containing a group of six positively charged amino acids (4 arginine, 2 lysine).  
This domain interacts with the negatively charged heparin sulfate proteoglycans 
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on the cell surface or in the extracellular matrix (ECM).  
    ECSOD has a proteolytic cleavage site next to the heparin binding domain.  
The proteolysis of the heparin binding domain can occur partially, to produce a 
tetramer with low affinity for heparin (type B), or completely, so all of the 4 
subunits lack the heparin-binding domain to produce tetramer with no affinity for 
heparin (type A).  If none of the subunits undergo proteolysis, the tetramer has a 
strong affinity for heparin (type C).  Type A and type B are found circulating in 
plasma, while type C remains bound to the ECM, but can be released into 
circulation by displacing it with heparin.  The tissue bound forms constitute ~ 99% 
of the total ECSOD (Fukai et al., 2002). 
 
ECSOD tissue distribution and expression regulation 
In contrast to the ubiquitous expression of Cu,ZnSOD and MnSOD, ECSOD 
expression is restricted to several tissues.  In mammalians, ECSOD expression 
is highest in lung, kidney and aorta, while the heart and brain have lesser 
amounts (Folz et al., 1997).  On the cellular level, a higher level of ECSOD 
expression was observed in alveolar type II cells, lung macrophages, vascular 
smooth muscle cells, endothelial cells and some fibroblast cells.  
The mechanism involved in ECSOD expression regulation is not well-
understood.  SP1/SP3 regulates ECSOD expression in human and mouse liver 
cell lines and lung fibroblast cell lines (Zelko et al, 2004; 2008).  In human 
vascular smooth muscle cells and lung alveolar type II cells, inflammatory 
cytokines such as interferon (IFN)-γ and IL-4 upregulate the expression of 
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ECSOD mRNA and protein while tumor necrosis factor (TNF)-α downregulates 
the expression of ECSOD.  Vasoactive factors such as histamine, vasopressin, 
oxytocyn, endothelin-1, serotonin, and heparin markedly increase enzyme levels 
in cultured arterial smooth muscle cells (Fukai et al., 1999).  Also, exercise 
training and Angiotensin II upregulate ECSOD expression in smooth muscle cells 
(Fukai at al., 1999, 2000).  In addition, ECSOD expression is uniformly 
downregulated by a wide variety of oxidizing agents, such as xanthine oxidase, 
paraquat, and t-butyl hydroperoxide in fibroblasts, although the mechanisms 
involved are not clear (Stralin and Marklund, 1994). 
 
ECSOD and cardiovascular disease  
In the cardiovascular system, ECSOD is highly expressed in blood vessels, 
particularly arterial walls.  Also, ECSOD activity is 10-fold higher in the vessel 
wall than in other tissues and constitutes up to 70 % of the total SOD activity in 
aorta.  A body of evidence shows the protective role of ECSOD in the 
cardiovascular system. ECSOD expression is reported to be reduced in patients 
with coronary artery disease while overexpression of ECSOD in vascular 
endothelial cells can protect against the oxidation of low-density lipoprotein (LDL), 
a major contributing factor to the formation of atherosclerosis (Takatsu et al., 
2001; Laukkanen et al., 2001).  These data suggest that the low ECSOD 
expression/activity contributes to the endothelial dysfunction in patients with this 
disease.  ECSOD also plays an important role in reducing myocardial infarct size 
and preserving cardiac function.  For example, recombinant human ECSOD 
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preserves cardiac function and reduces the level of tissue ROS following 
ischemia/reperfusion in rat isolated hearts (Sioquist et al., 1991).  ECSOD-
transgenic mice show greater preservation of myocardial function after global 
ischemia/reperfusion than their wild-type counterparts (Chen et al., 1996).  In 
addition, ECSOD can limit the interaction of •O2
- with NO• to preserve the 
bioavailability of NO.  Cardiac-specific ECSOD overexpression attenuates ROS 
levels and increases NO bioavailability in response to ischemia/reperfusion, thus 
protecting against reperfusion injury (Obal et al., 2012).   This action also 
prevents the excessive formation of the highly reactive and toxic peroxynitrite.  
 
Our questions and research goal 
    Kliment et al (2009) reported that lack of ECSOD leads to increases in 
myocardial apoptosis and significantly more left ventricle fibrosis in mice treated 
with DOX.  This means that ECSOD likely plays an important role in normal heart 
defense against DOX induced cardiotoxicity.  Thus, investigating the regulation of 
SOD3 expression in heart, especially when heart is exposed to DOX, may help 
us better understand how DOX causes heart damage.   However, there are no 
reports regarding how DOX affects SOD3 expression in heart, especially in 
different cell types of heart tissue.  Here, neonatal cardiomyocytes and cardiac 
fibroblastsfrom WT mice were treated with a range of DOX concentrations, and 
SOD3 mRNA and protein expression measured.  This study characterized the 
effects of DOX on SOD3 expression in these two cell types.  
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Materials and Methods 
Cell culture and treatment 
    Primary CM and CF were obtained from WT C57BL neonatal mice at 1–3 days 
of age and cultured as described in Chapter 3.  Cells were treated with varying 
concentrations of DOX for the indicated times and cells harvested for detection of 
SOD3 expression.  
 
RNA extraction and real-time quantitative PCR (qRT-PCR) 
    Total RNA extraction, cDNA preparation and RT-PCR were conducted as 
described in Chapter 2.  Primers and UPL probes used to detect SOD3 are 
shown in Table 4.1.  
 
Immunoblot Assay 
    Immunoblot assays were conducted as described in Chapter 4.  Rabbit anti-
ECSOD pAb was a generous gift from Dr. Ladislav Dory, University of North 
Texas.  
 
Statistical analysis 
    All data are expressed as the mean ± SD for n = 3 per group, as detailed in the 
Figure Legends.  In studies comparing multiple groups to the same control group, 
statistical analysis was performed with one-way ANOVA followed by Dunnett's 
post-test. 
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Results 
DOX decreased expression of SOD3 in CM 
    CM were treated with different concentrations of DOX for 24 h.  DOX 
concentrations were chosen based on the results of the MTT assay to avoid the 
high DOX concentrations that cause excessive cell death.  DOX decreased 
ECSOD mRNA (Figure 5.2A) and protein (Figure 5.2B) expression in a dose-
dependent manner.  In contrast, DOX significantly increased MnSOD protein 
expression levels, while it had no significant effects on Cu,ZnSOD expression 
(Figure 5.2B). DOX-induced cell apoptosis was demonstrated by PARP cleavage.  
    CM further treated with 0.5 µM DOX for various time periods showed that the 
down-regulation of ECSOD mRNA and protein level occurred at 8 h, 16 h and 24 
h after DOX treatment (Figure 5.3).   
       
DOX affectss on the expression of SOD3 in CF 
    CF were treated with various concentrations of DOX for 24 h, and showed that 
the lowest concentration of DOX (0.5 µM) decreased ECSOD mRNA and protein 
expression.  However, the high concentration of DOX (3 µM) significantly 
increased the expression of ECSOD protein, with no significant change in 
ECSOD mRNA expression.  Dox treatment also increased MnSOD expression at 
high concentrations (1 and 3 µM) of DOX (Figure 5.4).  DOX-induced cell 
apoptosis was demonstrated by PARP cleavage.  
CF were further treated with 3 µM DOX for various time periods, and showed 
that the increase of ECSOD protein expression began about 16 h after DOX 
137 
 
treatment.  However, there was no obvious change in the mRNA expression 
(Figure 5.5).  
 
Discussion 
    A number of studies suggest that the administration of a wide variety of 
enzymatic and nonenzymatic antioxidants can protect against oxidant-induced 
tissue injury, both in animal models and in human.  Since ECSOD expression 
and/or activity are decreased in multiple diseases, it is interesting to entertain the 
idea of ECSOD as a potential target for therapy to improve antioxidant capacity 
and restore the redox balance.  Thus, a further understanding of the role of 
ECSOD in the pathogenesis of oxidant-mediated diseases as well as the 
regulatory mechanism of ECSOD expression will provide insight into the potential 
therapeutic possibilities of this protein. 
    Our study is the first to show the effects of DOX treatment on ECSOD 
expression in CM and CF.  It is important to note that the ECSOD expression in 
CM and CF showed different responses to DOX treatment.  This means that 
there must be different machinery that controls ECSOD expression in these two 
cell types.  We expect the decrease of ECSOD expression in CM to exacerbate 
the DOX-induced oxidative stress, while the increase of ECSOD in CF could 
present the cellular response to this stress.  How these two sources of ECSOD 
coordinate with each other and how these ECSOD from different sources 
contribute to DOX-induced pathological changes in heart will be an important 
avenue to investigate.           
138 
 
In addition, compared to CMs, CFs have much higher ECSOD expression at 
both mRNA and protein levels (Figure 5.6).  The different basal levels of ECSOD 
expression and different expression regulation mechanisms in CM and CF 
indicate that ECSOD expression in whole heart tissue needs to be evaluated 
carefully because measuring total ECSOD expression in heart is not able to 
distinguish changes of ECSOD expression in these two different cell populations. 
Another interesting finding is the inconsistent changes of ECSOD mRNA 
expression and protein expression in CF treated with 3 µM DOX.  The disparity 
between ECSOD mRNA and protein expression are also reported in other cells 
(Folz et al., 1994).  These data indicate a role of post-transcriptional regulation in 
maintaining optimal enzyme levels in various tissues and in response to various 
stressors.  
    Based on these data, many further studies will be important, such as 
investigating post-transcriptional modulation of ECSOD, rates of protein 
synthesis and secretion, and the extent of protein degradation following DOX 
treatment.  These studies will help us better understand the expression 
regulation of ECSOD, and how this contributes to DOX induced cardiotoxicity.  
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Figure 5.1. Schematic diagram of ECSOD functional domains in protein.  
The ECSOD protein can be divided into four functional domains: (1) the signal 
sequence, cleaved during synthesis; (2) the glycosylated N-terminus; (3) the 
catalytic region, which bears the highest level of homology to Cu,Zn SOD; (4) the 
positively charged heparin-binding domain. 
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Figure 5.2. DOX treatment increased MnSOD but decreases ECSOD 
expression in CM culture in a dose-dependent manner.  CMs were treated 
with varying concentrations of DOX for 24 hr, then mRNA expression of SOD3 
was measure by real-time PCR (A) and protein expression of Cu,ZnSOD, 
MnSOD and ECSOD was detected by Western blot (B).  DOX-induced cell 
apoptosis was demonstrated by PARP cleavage. Each bar represents the mean 
+ SD. (n=3, *, p < 0.05 by Dunnett's post-test after one-way ANOVA).   
A 
B 
141 
 
 
 
                   
 
                   
Figure 5.3. DOX treatment decreased ECSOD expression in CM culture.  
CMs were treated with 0.5 µM DOX for varying time periods, and mRNA 
expression of ECSOD was measured by real-time PCR (A).  Protein expression 
of ECSOD was detected by Western blot (B).  DOX-induced cell apoptosis was 
demonstrated by PARP cleavage. Each bar represents the mean + SD. (n=3, *, p 
< 0.05 by Dunnett's post-test after one-way ANOVA). 
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Figure 5.4. DOX treatment changes expression of superoxide dismutases in 
CF culture in a dose-dependent manner.  CFs were treated with varying 
concentrations of DOX for 24 hr, and mRNA expression of ECSOD was 
measured by real-time PCR (A) and protein expression of Cu,ZnSOD, MnSOD 
and ECSOD was detected by Western blot (B).  DOX-induced cell apoptosis was 
demonstrated by PARP cleavage. Each bar represents the mean + SD. (n=3, *, p 
< 0.05 by Dunnett's post-test after one-way ANOVA).   
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Figure 5.5. DOX (3 µM) treatment increased ECSOD expression in CF 
culture. CFs were treated with 3 µM DOX for varying time periods, and mRNA 
expression of ECSOD was measured by real-time PCR (A).  Protein expression 
of ECSOD was detected by Western blot (B). DOX-induced cell apoptosis was 
demonstrated by PARP cleavage.  Each bar represents the mean + SD. (n=3, *, 
p < 0.05 by Dunnett's post-test after one-way ANOVA).  
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Figure 5.6. CF has higher ECSOD expression compared to CM.  mRNA 
expression of ECSOD was measure by real-time PCR (A) while protein 
expression of ECSOD was detected by Western blot (B).  Each bar represents 
the mean + SD. (n=3, *, p < 0.05 by Student t test).  
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Chapter Six 
 
Conclusion, general discussion and future studies 
 
Conclusion and general discussion 
The ATP-dependent efflux transporter MRP1 has been a major subject of 
scientific and clinical interest ever since its first characterization in 1992 (Cole et 
al., 1992).  Due to its role in multidrug resistance development in cancer cells, 
MRP1 is considered as a diagnostic marker and a therapeutic target to increase 
the efficacy of a variety of chemotherapy drugs, including anthracyclines 
(Schaich et al., 2005; Faggad et al., 2009; He et al., 2011).  In those situations, 
inhibiting MRP1 through pharmacological inhibitors is a potential approach to 
overcome the anti-cancer drug resistance.  However, based on its ability to efflux 
a wide range of endo-/xenobiotics, MRP1 has important physiological functions in 
normal tissues in unstressed or stressed conditions.  Thus, generally inhibiting 
MRP1 through pharmacological inhibitors may impair the normal tissues’ defense 
ability.  So far, the functions of MRP1 in normal tissue defense have not been 
investigated in depth compared to its effects on drug therapy efficacy in cancer.  
The work presented in this dissertation investigated the role of MRP1 in the 
defense of the normal mouse heart.  Specific emphasis was put on its potential 
protective function in chemotherapy drug DOX-induced cardiotoxicity, since 
DOX-induced cardiotoxicity is a severe dose-limiting side effect in cancer 
patients receiving this effective anti-cancer medicine.   
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DOX-induced heart failure is now widely recognized as a high risk 
complication of cancer chemotherapy experienced by a growing number of 
cancer survivors.  However, there are very few approaches with limited positive 
effects to prevent or alleviate this life-threatening toxicity.  DOX causes oxidative 
stress in cardiac tissue by promoting the generation of ROS, which further 
induces the damage to macromolecules, including protein, DNA and lipid.  Thus, 
identifying and studying the genes that may be involved in the oxidative stress 
regulation will be useful to find the potential strategies to reduce or even prevent 
DOX-induced cardiotoxicity.   
The clinical data showing the correlation between SNPs of MRP1 and patients’ 
susceptibility to DOX-induced cardiotoxicity are informative (Cole., 2014b).  
These data imply that MRP1 is involved in the heart’s defense against DOX 
toxicity.  Further functional studies in our laboratory show that HEK cells that 
overexpress an MRP1 SNP (Gly671Val) are more sensitive to DOX toxicity 
compared to cells expressing WT MRP1.  This MRP1 SNP actually impairs more 
than 85% of MRP1’s ability to efflux GS-HNE, resulting in a significantly higher 
intracellular accumulation of GS-HNE (Jungsuwadee et al., 2012).  These data 
suggest that MRP1 modulates the cells’ sensitivity to DOX, and this is 
accomplished not simply by effluxing DOX, but by effluxing other important 
substrates, such as GS-HNE.  To test this hypothesis in heart tissue, WT and 
Mrp1-/- mice were used as a model.  The unique advantage of this model is that 
unlike human MRP1, murine Mrp1 is not able to efflux DOX, but murine Mrp1 
retains the ability to efflux other substrates of human MRP1, such as GSH, 
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GSSG and GS-HNE.  Therefore, the Mrp1-/- mouse provides a good model to 
examine the role of Mrp1 in DOX-induced cardiotoxicity separately from Mrp1 
effects on DOX retention.  
 
The role of Mrp1 in normal heart defense against DOX toxicity 
    The data presented in this dissertation provide insights into the role of Mrp1 in 
heart defense against DOX toxicity using both in vivo and in vitro model systems.  
In Chapter 2 of this dissertation, WT and Mrp1-/- mice were treated chronically 
with DOX, followed by measurement of cardiac function and heart damage.  
Mrp1-/- mice showed more severe body weight loss and delayed recovery from 
hemotoxicity.  These data imply that Mrp1 could play important protective roles in 
organs other than the heart.  These findings are consistent with the published 
data demonstrating that Mpr1 protects normal tissues like skin and brain against 
xenobiotics.  Further echocardiogram studies showed that there is no difference 
in left ventricular function between saline treated WT and Mrp1-/- mice.  However, 
following chronic DOX treatment, Mrp1-/- mice had significantly more severe left 
ventricle dysfunction compared to WT mice, presenting as significantly lower 
fractional shortening and ejection fraction.  This functional change was consistent 
with the higher BNP expression level found in DOX treated Mrp1-/- mouse heart.  
These observations suggest that under normal physiological conditions, loss of 
Mrp1 does not affect cardiac function; however, under stressful conditions, such 
as treatment with DOX, and when the stress exceeds a certain threshold, the 
heart of Mrp1-/- mice showed an impaired defensive ability to respond to the 
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stress, consequently resulting in functional damage.  These data well support our 
initial hypothesis regarding the protective role of Mrp1 in heart.   
The extent of apoptosis was also measured in heart sections from mice 
chronically-treated with DOX.  The quantitative data showed that following DOX 
treatment, Mrp1-/- mouse heart had significantly more apoptotic cells than WT 
mice.  We believe this higher apoptosis contributes to the more severe cardiac 
functional damage in Mrp1-/- mice.  This is consistent with our  previous electron 
microscopy studies, which show that compared to WT mice, Mrp1-/- mice have 
more nuclear injury, including early apoptotic changes in nuclei in heart after a 
single intravenous administration of DOX.  The effects of Mrp1 on DOX-induced 
apoptosis were also observed in our in vitro study, which used isolated neonatal 
mice cardiomyocytes and cardiac fibroblasts from WT and Mrp1-/- pups.  In CM 
and CF cultures, the same concentration of DOX showed that compared to WT 
cells, Mrp1-/- cells are more sensitive to DOX toxicity, indicated by lower cell 
survival, more PARP cleavage, more caspase3 cleavage and more γH2A.X 
expression.  Those data indicate that Mrp1 similarly protects CM and CF against 
DOX cytotoxicity.  Taken together, these data demonstrate the cardiac protective 
role of MRP1 in both in vivo and in vitro model systems.    
 
The role of Mrp1 in GSH/GSSG homeostasis 
   The work presented in this dissertation further examined the mechanisms by 
which Mrp1 protects in the heart following DOX treatment, especially in GSH 
homeostasis, GS-HNE accumulation and protein oxidative damage.   
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    In Chapter 4 of this dissertation, loss of Mrp1 increased basal intracellular 
levels of GSH and GSSG in treatment-naïve and saline-treated heart tissue, CM 
culture and CF culture.  However, no differences were observed in the 
expression of GSH enzymes between genotypes in the absence of DOX 
treatment.  These data are consistent with the reported function of Mrp1 to efflux 
GSH and GSSG.   
    DOX treatment further increased intracellular levels of GSH and GSSG in 
Mrp1-/- CM and CF.  This is likely due to the increased GSH synthesis since the 
expression of GSH synthetic enzymes, GCLc, GCLm and GSS, was increased in 
DOX-treated Mrp1-/- cells only.  Since all the three enzymes are regulated by 
Nrf2, we examined whether the Nrf2 pathway was activated in DOX treated 
Mrp1-/- cells.  We found that the expression of Nqo1 and HO-1, two additional 
downstream genes in the Nrf2 pathway, were also significantly higher in DOX 
treated Mrp1-/- cells compared to WT cells.  We concluded that in response to 
DOX treatment, the Nrf2 pathway was activated in Mrp1-/- cells, and increased 
the transcription of its downstream genes, including the GSH synthesis enzymes 
and finally contributed to the elevated intracellular level of GSH and GSSG.  
However, the elevated GSH was not able to protect Mrp1-/- cells against DOX-
induced oxidative stress.  Finally, although the elevated GSH level was not able 
to protect Mrp1-/- mouse heart or Mrp1-/- cells against DOX toxicity, we found a 
significantly lower GS-HNE level in treatment-naïve mouse heart (Deng et al., 
submitted).  These data mean that the higher GSH level in Mrp1-/- mouse heart 
does protect against ‘background’ levels of oxidative stress.   
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An important observation is that Mrp1 deficiency increases the GSH level in 
the heart and in CM/CF.  This means that MRP1-mediated efflux of GSH plays 
an important role in maintaining the normal intracellular GSH level.  Usually, GCL 
is recognized as the major determinant of cellular GSH homeostasis.  It catalyzes 
the first and rate-limiting step in de novo synthesis of GSH.  The expression and 
activity of GCL is tightly controlled by a complex regulation at several levels, 
including: transcriptional activation by oxidative stress; reversible formation of the 
disulfide bond between its two subunits (GCLc and GCLm); and feedback 
inhibition by GSH.  In out study, without a significant difference in GCLc and 
GCLm expression, the treatment-naïve and saline-treated Mrp1-/- mice heart and 
Mrp1-/- CM/CF have a higher GSH level compared to WT mice heart and cells.  
These data indicate the importance of Mrp1-mediated efflux in intracellular GSH 
level regulation, regardless of the GCL expression and activity changes.  In 
addition, compared to WT cells, the DOX treated Mrp1-/- cells have significantly 
higher expression of GCLc and GCLm, which caused a further increase in the 
GSH pool, although there is already a higher basal level of GSH in Mrp1-/- cells.  
All of these data indicate that GCL is not the only sensor and factor that is 
responsible for the intracellular GSH level, and that Mrp1-mediated efflux is 
another important determinant. 
 
The role of Mrp1 in HNE detoxification 
    Another important consequence of DOX-induced oxidative stress is lipid 
peroxidation.  HNE is one of the major toxic products of lipid peroxidation and 
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conjugation with GSH is its major metabolism pathway.  GS-HNE was 
investigated in this study because our previous work demonstrated that Mrp1 is 
the sole, or at least the most important, transporter in mouse heart to efflux GS-
HNE.  We expected that loss of Mrp1 would cause GS-HNE accumulation in 
mouse heart, especially under the oxidative stress induced by DOX.  In Chapter 
4, DOX treatment significantly increased the GS-HNE detected in mice heart 
tissue.  These data were consistent with the expectation that DOX cause 
oxidative stress in cardiac tissue, leading to lipid peroxidation.  However, unlike 
our expectation, there was no difference in GS-HNE levels between WT and 
Mrp1-/- mouse heart. We believe this could be due to the complex compensating 
effects in Mrp1-/- mouse heart.  Thus, Mrp1 deficiency may saturate other 
detoxification pathways of HNE.  To answer this question, we would need to 
quantitate other metabolites of HNE, such as DHN, HNA, GS-DHN and GS-HNA.  
More information regarding the biological activities of these HNE metabolites and 
whether they are substrates of Mrp1 will also be helpful in evaluating the effects 
of Mrp1 on HNE detoxification. 
 
The role of MRP1 in cellular compartments  
    In Chapter 2 and 3, our studies show that the loss of Mrp1 causes more 
nuclear injury in mouse heart following acute DOX treatment, more apoptosis in 
hearts of mice treated chronically with DOX, and more cell apoptosis and DNA 
damage in CM/CF culture.  Thus, it appears that the most severe damage 
caused by Mrp1 deficiency mainly occurs in the nucleus.  This raises a question 
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regarding the potential function of Mrp1 in nucleus.  A previous study in our 
laboratory has shown that Mrp1 is localized in sarcolemmal membrane of 
cardiomyocytes in heart in untreated mice.  However, upon treatment with DOX, 
the expression of Mrp1 is significantly increased in the heart mitochondrial 
fraction.  However, we did not examine the nuclear localization of Mrp1 in heart 
tissue.  Although a nuclear localization sequence was not found in MRP1, two 
publications from the same research group reported that the nuclear MRP1 
contributes to multidrug resistance in human mucoepidermoid carcinoma cell 
lines (Cai et al., 2011; Cai et al., 2013).  In addition, Rajagopal et al (2003) 
reported that human MRP1 is present in a perinuclear region positive for 
lysosomal markers, and may rescue cancer cells by sequestering the toxic 
substance away from the nucleus.  However, further studies are needed to 
determine whether this occurs in heart.  
  In addition, loss of Mrp1 impairs GSH efflux and could cause lower GSH 
levels in the extracellular environment and finally accelerate oxidative damage in 
the extracellular environment.  Extracellular GSH can also be broken down in the 
extracellular space by γGT and dipeptidase, thus producing cysteine.  The lower 
extracellular GSH concentration could affect the cysteine/cystine balance, which 
is also critical for maintaining extracellular redox status.  In Chapter 4, our in vitro 
studies found that exogenous cell impermeable GSH (10 mM) eliminated the 
difference in cell viability between DOX treated-WT and Mrp1-/- cells.  Also, the 
expression of ECSOD, the only SOD existing in the extracellular environment, is 
reduced in saline and DOX-treated Mrp1-/- CM.  The lower ECSOD expression 
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may contribute to the Mrp1-/- CM’s sensitivity to DOX.  These data imply 
potential effects of Mrp1 on redox status in the extracellular environment, and 
indicate the need for further studies. 
Clinical significance of this study 
During the past two decades, the focus of MRP1 research has been on the 
negative effects of MRP1 expression, especially its contributions to multidrug 
resistance in cancer cells.  Therefore, the use of MRP1 inhibitors in the treatment 
of cancer has been the main therapeutic goal (Burkhart et al., 2009; Sirisha et al., 
2011; Zhang et al., 2014; Ma et al., 2014).  Although this may be beneficial to 
sensitize multidrug resistant cancer cells to anticancer drugs, our research shows 
that inhibiting MRP1 in the heart may potentiate the chemotherapy drug-induced 
cardiotoxicity.  These studies provide critical information regarding the potential 
adverse sequelae of introduction of MRP1 inhibitors as adjuncts to clinical 
chemotherapy of multidrug resistant tumors.  In addition, genetic variants of the 
MRP1 gene have been found in clinical patients and multiple SNPs are found to 
be associated with cancer patients’ susceptibility to DOX-induced cardiotoxicity.  
Our study may provide some explanations for these clinical observations if the 
SNPs impair MRP1’s expression or activity.  It will potentially further help to 
identify these susceptible patients and modify chemotherapy strategies for these 
individuals and thus prevent such drug-induced toxicity.   
 
Future studies 
Based on the results in this dissertation, the following experiments warrant 
154 
 
future investigation: 
 
What are the consequences of increased GSSG in Mrp1-/- mouse heart? 
    In addition to the higher GSH level, we also demonstrated a significantly 
higher GSSG level in DOX-treated Mrp1-/- mouse heart and Mrp1-/- CM/CF.  
Reversible protein S-glutathionylation as a common feature of redox signal 
transduction is able to regulate the activities of several redox sensitive proteins.  
Increased intracellular GSSG concentration following microinjection or inhibition 
of the efflux through Mrp1 has been shown to cause glutathionylation of cysteine-
containing proteins, and consequently change their cellular function, finally 
causing cell death (Park et al., 2009).  Investigating the effects of elevated GSH 
and GSSG levels in Mrp1-/- mouse heart and cells on glutathionylation 
modification of proteins could provide new insights regarding how Mrp1 
modulates the sensitivity to DOX induced cardiotoxicity. 
 
What are the concentrations of HNE and HNE metabolites?  
As we discussed above, in addition to conjugation with GSH, HNE has other 
detoxification pathways.  Measurement of the concentration of other HNE 
metabolites, such as HNA, DHN, GS-HNA, GS-DHN and HNE itself will help to 
better understand how loss of Mrp1 affects the detoxification of HNE and the 
consequence of lipid peroxidation.  
 
Does Mrp1 protect heart through other functions in addition to its transport 
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activity?  
    Another ABC transporter, P-glycoprotein (Pgp) /MDR1, has been 
demonstrated to have anti-apoptotic activity independent of its transporter activity 
(Tainton et al., 2004).  In that study, lymphoma cells expressing ATPase-mutant 
Pgp cannot efflux chemotherapeutic drugs but remained relatively resistant to 
apoptosis induced by vincristine.  In addition, the anti-apoptotic effect of this 
mutant Pgp is not affected by antibodies that inhibit the efflux function of the 
protein.  Those data are consistent with a dual activity model for Pgp-induced 
MDR involving both ATPase-dependent drug efflux and ATPase-independent 
inhibition of apoptosis.  It would be important to investigate whether other 
functions of Mrp1 beyond its transport activity could contribute to the protective 
role of Mrp1 in DOX toxicity.  Use of an Mrp1-specific inhibitor or development of 
cells expressing Mrp1 with mutations that delete its ability to transport will help to 
answer this question.  Further investigation of Mrp1’s localization especially in 
mitochondria or nucleus and Mrp1’s interaction with anti-apoptotic proteins may 
provide more insight. 
 
Use human induced pluripotent stem (iPS) cells derived CM to study the 
role of human MRP1 against DOX toxicity.  
Since murine Mrp1 does not efflux DOX, here we took advantage of the 
mouse model to investigate the potential function of Mrp1 in oxidative stress 
regulation.  However, this difference between human MRP1 and mouse Mrp1 
may limit the clinical significance of this study.  Human induced pluripotent stem 
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(iPS) cell-derived cardiomyocytes provide a good model to aid drug discovery 
and improve the predictability of drug efficacy and toxicity screens.  Investigation 
of the function of human MRP1 in these cells would/could provide valuable 
insight regarding the importance of MRP1 in DOX-induced cardiotoxicity in 
patients.   
 
What are the concentrations of GSH and GSSG in specific intracellular 
organelles? 
    In recent years, increasing evidence demonstrates the existence of well-
defined compartments of redox systems within cells, each exhibiting a unique 
redox environment (Circu et al., 2008).  Intracellular GSH is compartmentalized 
within the mitochondria, nucleus and endoplasmic reticulum (ER), all of which 
constitute separate redox pools that are distinct from the cytoplasmic pool in 
terms of distribution of the GSH and GSSG forms, their redox potential and their 
control of cellular activities.  Mrp1 is localized in plasma membrane and in the 
membrane of intracellular organisms, including lysosome, trans-Golgi vesicles 
and mitochondria, as shown in studies using techniques such as Western blot, 
immunofluorescence, and immunogold electron microscopy (Rajagopal et al., 
2003; Gennuso et al., 2004; Jungsuwadee et al., 2009).  Thus, it will be very 
important to determine whether such localized expression of Mrp1 affects 
GSH/GSSG homeostasis in these distinct cell compartments.  However, precise 
quantification of the GSH and GSSG in specific intracellular compartment is 
difficult.     
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    In summary, this study is the first to document a protective role of Mrp1 in 
DOX-induced cardiotoxicity despite equal DOX concentrations.  It gives critical 
information regarding the potential adverse sequelae of introduction of MRP1 
inhibitors as adjuncts to clinical chemotherapy of multidrug resistant tumors.  It 
will also potentially help to identify the susceptible patients and modify 
chemotherapy strategies for these individuals and thus prevent such drug-
induced toxicity.  Further studies as we discussed above will provide essential 
information to elucidate the mechanism of Mrp1-mediated cardiac protection. 
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Appendices 
 
Appendix A  
List of abbreviations 
 
ABC ATP-binding cassette 
ADP Adenosine diphosphate 
ARE Antioxidant response element 
ATP Adenosine triphosphate 
BNP B-type natriuretic peptide 
CM Cardiomyocytes 
CF CDHNardiac fibroblasts 
Cu,ZnSOD/SOD1 Cu,Zn-superoxide dismutase 
DHN 1,4-dihydroxy-2-nonene 
DOX Doxorubicin 
ECSOD/SOD3 Extracellular superoxide dismutase 
EF Ejection fraction 
Eh Redox potential 
FS Fractional shortening 
GAPDH Glyceraldehyde-3-phosphate dehydrogenase 
GCLc Glutamate-cysteine ligase catalytic subunit 
GCLm Glutamate-cysteine ligase regulatory subunit 
Gpx Glutathione peroxidase 
GR Glutahione reductase 
Grx Glutaredoxin 
GST Glutathione S-transferase 
GSS Glutathione synthetase 
GSH Glutathione 
GSSG Glutathione disulfide 
GS-HNE Glutathione conjugates of 4-Hydroyx-2-nonenal 
 
γGT γ glutathione transpeptidase 
HO-1 Heme oxygenase 1 
HNA 4-hydroxy-2-nonenoic acid 
HNE 4-Hydroyx-2-nonenal 
- 
Hydroxy 
- 
2 
- 
HPLC High performance liquid chromatography 
HRP Horseradish peroxidase 
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iPS cells induced pluripotent stem cells 
LVEF Left ventricular ejection fraction 
LVFS Left ventricular fractional shortening 
LVIDd Left ventricular end-diastolic dimension 
LVIDs Left ventricular end-systolic dimension 
LVPWd Left ventricular diastolic posterior wall thickness 
LVPWs Left ventricular systolic posterior wall thickness 
LTC4 Leukotriene C4 
LY Lymphocyte 
MDA Malondialdehyde 
MnSOD/SOD2 Mn superoxide dismutase 
MBB Monobromobimane 
Mrp1/Abcc1 Multidrug resistance-associated protein 1 
Mrp1-/- Mrp1 knock out 
 MRM Multiple reaction monitoring 
MSD Membrane spanning domain 
NBD Nucleotide binding domain 
NQO1 NAD(P)H dehydrogenase, quinone 1 
Nrf2 Nuclear factor-like 2 
Pgp P-glycoprotein 
Prx Peroxiredoxin 
RNS Reactive nitrogen species 
ROS Reactive oxygen species 
SNPs Single nucleotide polymorphisms 
TMD Transmembrane domain 
Trx Thioredoxin 
WBC White blood cell 
WT Wild type 
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Appendix B  
Isolation of neonatal mice cardiomyocytes and cardiac fibroblasts 
 
Solutions: 
Hanks balanced salt solution without Ca2+ and Mg2+ (14185-052, Life 
Technologies, CA) 
Enzyme solution: 10mg collagenase in 30 m l HBSS (collagenase type 2: 
Worthington Biochemical Corp., Lakewood, NJ) 
DMEM (10965, Life Technologies, CA) 
Fetal bovine serum (FBS) (10438-026, Life Technologies, CA) 
Penicillin/streptomycin (15140-122GIBCO, Grand Island, NY) 
 
Protocol: 
1. 1–3 days old pups are sacrificed by cervical dislocation. The hearts are 
removed and placed in cold HBSS without Ca2+ and Mg2+. 
2. The hearts are washed with HBSS for several times to remove most of the 
red blood cells and the atria are removed and discarded. 
3. The ventricles are transferred to 1 mL of enzyme solution and minced into 
small pieces. 
4. Tissue is placed into a 10 mL beaker and a small stir bar is added. 
5. 4 mL of enzyme solution is added for a total of 5 mL. The beaker is placed 
in a dish of warm water bath (37°C) on a stir plate and the tissues agitated 
for 10 min.  
6. At the end of each cycle of agitation, the tissue pieces are allowed to settle. 
Then, the supernatant is removed and added to a 15 mL centrifuged tube 
with 0.5 mL FBS with a final FBS concentration of 10% and centrifuged for 
10 min at 800 rpm. (Note: the supernatant from the first digestion may 
contain mainly red blood cells and should be discarded)   
7. At the end of centrifugation, the supernatant is discarded and the cell pellet 
is resuspended in 2 mL DMEM and placed in a 6-well culture dish.  
8. Step 5 -7 are repeated until all tissue has been digested. This can take up 
to 10 individual digests for the ventricular tissue. 
9. After pre-plating period (about 2 hours) to allow the non-myocytes 
predominantly fibroblasts to adhere to the plastics, the suspensions mainly 
including cardiomyocytes are collected form cell culture dish by gently 
washing with culture medium and collected in a 15 mL centrifuge tube and 
centrifuged at 800 rpm for 10 min.  The cell pellet mainly including 
cardiomyocytes are resuspended in DMEM medium and plated in cell 
culture dish with appropriate cell density (about 105/cm2). The non-
myocytes predominantly fibroblasts which adhere to the plastics before are 
maintained in DMEM medium with 10% FBS. 
10. CM numbers are determined by counting living cells (with Trypan blue) 
using a hemocytometer.  
11. For CM culture, 100 μmol/L Bromodeoxyuridine (Sigma Chemical Co) is 
added during the first 48 h of culture to prevent proliferation of 
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nonmyocytes.   
12. CF cultures are used for experiments after two passages to eliminate other 
nonmyocytes. 
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